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Summary: 
 
Introduction: Family history (FH) of colorectal cancer (CRC) is a frequent reason 
for referral to Clinical Genetics in the UK. The British Society of 
Gastroenterologists (BSG) guideline stratifies patients to risk categories 
(low/population, low-moderate, high-moderate and high) according to FH. 
Individuals with Lynch syndrome are classified differently to those who have a 
high-risk FH, but no high penetrance mutation. We investigated how effectively 
BSG guidelines categorise people at increased risk of CRC. 
 
Methods: FH data was obtained for all unaffected people with a family history of 
CRC, referred to Tayside clinical genetics from 2000-2009. Risk category 
according to BSG guidance was assigned de novo. Individuals who went on to 
develop adenomatous polyps or CRC were identified by record linkage.  
 
Results: 1120 patients were identified and after exclusion criteria, there were 
728 non-polyposis patients (288 low-risk, 316 moderate-risk and 121 high-risk, 
including 31 mutation carriers). 8 invasive CRC developed, 2 in low, 3 in 
moderate and 3 in high-risk groups. There was no significant difference in the 
Relative Risk (RR) of cancer development between groups. The only significant 
finding was an increased risk of CRC in mutation carriers, RR 9.290 (1.3557-
63.6653). Kaplan-Meier analysis demonstrated no significant difference in cancer 
rates between groups. There was a significantly higher risk of polyp detection in 
the high-risk group compared to the low-risk group. Kaplan-Meier analysis 
demonstrated a significantly higher likelihood of polyp detection in the high-risk 
group when compared to both low and moderate-risk groups.  
 
Conclusions: Presence of mutation seems to be the best predictor of cancer 
risk. Colonoscopic surveillance may be effective in reducing the cancer incidence 
in the moderate and high-risk groups. The study re-affirms that no colonoscopic 
screening is required in the moderate-risk group aged less than 50. Furthermore, 
it may suggest that less screening is required in the high-risk group beyond the 
age of 50. 
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Chapter 1: Introduction 
 
1.1 Overview of colorectal cancer 
 
1.1.1 Epidemiology 
 
According to the International Agency for Research on Cancer data in 2018, 
colorectal cancer (CRC) ranks as the third most common cancer worldwide, with 
1.8 million new diagnoses.(1) The incidence patterns are reflected equally in both 
males and females, however, there is geographical variation with the highest 
incidence in Australia and New Zealand and the lowest incidence in Western 
Africa. When comparing more with less developed regions, 55% of the cases 
occur in the former.(1,2) In the UK, CRC accounts for 12% of all new cancer 
cases, with 55% of those occurring in males. The rates have remained stable 
over the last decade; it is estimated that 1 in 14 men and 1 in 19 women will 
develop CRC in their lifetime.(3) The incidence is strongly correlated with age, 
rising steeply from around the age of 50 (See Figure 1).(3) Mortality rates also 
vary worldwide, with fewer deaths in more developed regions, reflecting better 
survival due to better treatment.(1) Even though mortality rates have decreased 
by 42% in the last 50 years, CRC remains the second most common cause of 
cancer death in the UK. Mortality also increases with age, with higher rates in 
males above the age of 60 years old (See Figure 2).(3–6) 
 
In Scotland, the incidence of CRC for the period of 2013-2017 was 15,127 cases. 
(7) Mortality rate was 31.1%, which is higher than England (24.4%) in 2017.(6,7) 
Age specific incidence in Scotland follows the same trend as the rest of the UK; 
however, the age-specific mortality rate is higher between ages 70-74, rather 
than 80-84 as shown in Figure 2. 
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Figure 1 Incidence of CRC by age and gender. Figure from source (3). 
 
 
 
 
 
 
Figure 2 CRC mortality by age and gender. Figure from source 7. 
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1.1.2 Population Screening:  
 
Due to the increased incidence of CRC, as well as the fact that most cancers 
were identified at a later stage (See Section 1.2), a method needed to be 
implemented to detect CRC at an early, curable stage. Thus, a screening 
programme, which aims to detect non-visible blood in the faeces- faecal occult 
blood test (FOBt) was implemented in various countries. A variety of high-quality 
trials were conducted to assess the effectiveness of this test. One of the first 
randomised controlled trials (RCT) included 45000 people aged 50-80 years who 
were randomised to receive no FOBt screening (control group) or receive FOBt 
screening every two years. The cumulative incidence of CRC development was 
significantly reduced in the intervention groups (relative risk 0.80, 95% CI 0.70 to 
0.90; p= 0.002).(8) Moreover, three RCTs conducted in the US, UK and Denmark 
revealed reduced mortality of CRC in people who undertook screening.(8–10) 
This was also confirmed in a Cochrane review and meta-analysis of these 
studies, revealing a reduction in mortality by 16% in the screened population 
(relative risk 0.84, 95% CI 0.78 to 0.90).(11) 
 
In the UK, bowel screening was implemented after pilot studies were conducted 
in England and Scotland.(12) The studies’ outcomes were in agreement with the 
previous RCTs, demonstrating a significant decrease in bowel cancer mortality. 
In England, Wales and Northern Ireland, screening is offered every two years 
between the ages of 60-74. However, people in England and Scotland that 
exceeded 74 years of age may be screened upon request whereas the rest of 
the countries do not accept requests. In Scotland, screening is implemented from 
50-74 years of age.(13) Within 6 months of invitation, it is estimated that around 
50% of the people who are invited across the UK are screened with a definitive 
result. Screening uptake is higher in females than in males across the whole of 
the UK.(14) Screening uptake data are available for England, showing a reduced 
uptake in the younger age groups (53.5% in 60-64 age group compared to the 
62% and 60.3% in the 65-69 and 70-74 age groups).(14) 
 
If the initial test is not definitive (unclear), two repeat FOBts are sent in England 
or a faecal immunochemical test (FIT) in Wales, Scotland and Northern 
 16 
 
Ireland.(3) People who have an abnormal result will have a colonoscopy, unless 
this method is deemed inappropriate or the person does not attend their 
appointment. People will have different management according to what is 
detected at the time of colonoscopy. If no abnormality is detected, the FOBt will 
be offered again every two years. 
 
Initial FOBt has a higher positivity rate because true positives are taken out of the 
population for subsequent (incident) screens. Following colonoscopy, adenomas 
are found in 48% of men and 35% of women in England, with a high proportion 
of those being intermediate or high risk. Bowel cancer is found in 12-15% of men 
and 8% of women who were investigated after an abnormal screening result.(14) 
After the initial screen, people with abnormal incident screens have about 5% 
chance of being diagnosed with CRC and 25% chance of having a benign polyp. 
Even though a number of people with CRC have been identified through FOBt, 
no study has compared FOBt to colonoscopy in order to determine the specificity 
or negative predictive value of the test in asymptomatic population. 
Approximately 60% of people with CRC will have abnormal FOBt 
result.(13,15,16) 
 
Since 2017, Quantitative faecal immunochemical testing (FIT) has been 
implemented as first-line screening method in the Scottish Bowel Screening 
programme, with the screening age group and the recall time remain the same. 
Studies have shown an increased uptake of the FIT test across gender, age and 
deprivation categories, which may be attributed to its simpler use and to the fact 
that it only requires one sample to be taken.(17,18) This test measures 
micrograms of human haemoglobin per gram of faeces (μg Hb/g faeces) rather 
than just the presence of blood; a result of more than 80 μg Hb/g faeces will be 
referred for further assessment with colonoscopy. It is also specific to human 
haemoglobin and is less likely to be affected by diet and certain medications. The 
positivity is higher when using FIT rather than FOBt (3.1% and 1.9% 
respectively). Moreover, FIT is a better positive predictor in identifying adenomas 
than FOBt (43.5% vs 40.00%). Even though FOBt is more accurate in identifying 
CRC, cancer detection is higher using FIT due to increased uptake and greater 
percentage of positive tests. Identified CRCs through colonoscopy after positive 
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FIT test were mostly (60.3%) in the first two stages of disease with no 
metastasis.(19,20) 
 
Even though the initial testing has no direct associated risks, it is possible that 
people might develop anxiety or have false reassurance due to a negative 
screening test. Furthermore, colonoscopy has a separate set of risks and 
complications, such as heavy bleeding, bowel perforation and even death. 
People in high risk categories such as those with previous diagnosis of CRC, 
colonic adenomas, inflammatory bowel disease and acromegaly have separate 
guidelines.(13) Different guidelines also apply to people with strong family history 
or genetic predisposition to CRC development (See Section 1.7).  
 
When considering the cost-effectiveness of the screening programme, in a meta-
analysis of 55 publications, all studies concluded that any form of CRC screening 
is more cost-effective or even cost-saving compared to no screening.(21) 
Furthermore, several studies have reported the superiority of FOBt either alone 
or in combination with other screening methods such as sigmoidoscopy in terms 
of cost-effectiveness for cancer mortality.(22–24) A recent study comparing the 
cost-effectiveness of FOBt with FIT, suggests that FIT is significantly (p<0.001) 
cost-saving and results in quality adjusted life years gains of 0.014 (95% CI 0.012 
to 0.017). However, due to the pressures on endoscopy services, alternative 
screening programmes are not feasible.(24,25) Furthermore, the impact of the 
screening programme on hospital diagnostic services must also be considered. 
Nevertheless, the benefits including cost-effectiveness as well as incidence and 
mortality outweigh the harms.(26)  
 
1.2 Pathology 
 
1.2.1 Polyps 
 
Polyps can be defined as small growths that can occur throughout the GI tract, 
most commonly in the colon. Polyps can either grow without stalks, called sessile, 
or protrude from the mucosa surface, termed pedunculated. Generally, polyps 
can be classified in non-neoplastic and neoplastic. There are three types of non- 
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neoplastic polyps, the first one known as hyperplastic which is thought to arise 
due to decreased epithelial turnover and devalued shedding, resulting in a “pile-
up” of goblet cells. The second, inflammatory polyp is part of a solitary rectal ulcer 
syndrome and patients can present with rectal bleeding, mucus discharge and 
inflammation in the anterior rectal wall. The third type of non-neoplastic polyp is 
called hamartomatous and can occur either sporadically or as components of 
some inherited syndromes (See Section 1.5). The most common type of 
neoplastic polyps are adenomas, which are infrequent in African and Asian 
countries but occur in nearly 50% of the Western population aged over 50. 
Adenomas can be pedunculated or sessile and can range from 0.3 to 10cm in 
diameter.  They are characterised by the presence of epithelial dysplasia, which 
can be identified histologically as nuclear hyperchromasia, elongation and 
stratification (See Figure 3). Adenomatous polyps can be sub-classified into 
tubular, tubulovillous or villous on the basis of their architecture; however, 
evidence suggests little clinical significance of this differentiation. Sessile 
serrated adenomas are most commonly found in the right colon, lack dysplasia 
and their malignant potential is similar to the typical adenomas.(27,28) 
 
Even though adenomas are benign lesions, evidence from epidemiological 
studies suggests that they are precursors of CRC. Studies show that the 
incidence by geographic location of CRC follows the adenoma pattern and that 
the prevalence of adenomas peaks at least 5 years prior to CRC development. 
Furthermore, malignant foci have been identified in adenomas as well as 
remnants of adenomas in CRC.(29–32) Removal of adenomas can decrease the 
incidence of CRC by up to 90% as well as mortality, further supporting that 
adenomas might be precursors of CRC.(33–35) The rate of transformation of 
adenoma to adenocarcinoma is around 0.25%.(36) There is a strong positive 
correlation between size of adenoma and risk of malignancy, with studies 
suggesting that around 40% of lesions larger than 4cm contain malignant foci. 
(27,29) 
 
The British Society of Gastroenterologists (BSG) have guidance on surveillance 
following adenoma detection.(37) The frequency of surveillance depends on the 
patient’s risk category, according to the number and size of adenomatous polyps 
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found at baseline colonoscopy (See Table 1 and Figure 4). During the 
endoscopy procedure, it is recommended that scanning of the colonic mucosa 
occurs both during insertion and withdrawal of the colonoscope to reduce the 
miss rate of small polyps. Pancolonic dye spraying is also used to aid in the 
detection of small flat polyps. It is also pivotal to completely excise the polyp, as 
studies have shown that a substantial percentage of CRCs develop at the site of 
previous polypectomy.(37–39) In inherited polyposis conditions, different 
guidelines apply (See Section 1.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Histology of adenomatous polyps in the colon. A. Tubular adenoma; B. Villous adenoma; C. Dysplastic 
epithelial cells; D. Sessile serrated adenoma. Picture taken from source (27). 
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Table 1 BSG risk criteria for adenomas. Information taken from source 27. 
BSG Risk Category Colonoscopy findings 
 
High risk 
 
≥5 small adenomas 
 
OR 
 
≥3 at least one ≥1 cm 
 
 
Intermediate risk 
 
 
3-4 small adenomas 
 
OR 
 
At least one ≥1cm 
 
 
Low risk 
 
1-2 adenomas 
 
AND 
 
Both small <1cm 
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Figure 4 Recommended surveillance according to colonoscopic findings. Ιnformation extracted from source 37. 
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1.2.2 The adenoma-carcinoma sequence 
 
Even though not all adenomas become malignant, an estimated of 85% of CRC 
are thought to have an adenoma precursor. There are various mechanisms 
involved in the pathogenesis of CRC and how carcinomas evolve from 
adenomas.(27,40,41) Both genetic and epigenetic abnormalities and molecular 
events are responsible for the adenocarcinoma formation. One of the most well-
established pathways is that of APC/β-catenin, which accounts for around 80% 
of sporadic CRC. APC is a tumour suppressor gene and a negative regulator of 
β-catenin. Loss of APC function leads to failure of degradation of β-catenin, 
leading to accumulation in the nucleus and increased transcription of genes such 
as MYC and Cyclin D1, involved in proliferation. The increased proliferation is 
followed by prevention of apoptosis due to activating mutations of the KRAS 
gene, which is seen in 50% of adenomas that are greater than 1 cm in diameter 
and in 50% of invasive CRC. Defects in DNA repair pathways can contribute to 
the accumulation of somatic mutations that lead to uncontrolled proliferation or 
enhanced survival of neoplastic cells. Constitutional and somatic mutations in 
DNA mismatch repair genes can cause instability of polyA tracts in the Epidermal 
Growth factor receptor gene (42) and other simple sequence repeats in genes 
involves in growth regulation such as TGFBR2 and BAX. Furthermore, complex 
mechanisms including the CpG island methylator phenotype (CIMP) have been 
implicated.(27,41,43,44) The mechanisms in which carcinogenesis occurs can 
overlap and are used in the molecular classification, as well as prognosis and 
management.(27)  
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1.2.3 Colorectal Cancer Staging  
 
CRC tumours are typically classified by the criteria of the America joint committee 
of cancer (AJCC) with the Tumour-Node-Metastases (TNM) system.(45) Usually, 
T1 and T2 have tumours just invading through the submucosa but not into the 
muscular propria; their 5-year survival rate is 75%.(46) However, stage IV has 
very poor prognosis, with 6% survival rate.(46) Duke’s staging is also widely used 
to classify CRC (See Table 2).(47) Treatment depends on staging, always taking 
into account the person’s fitness depending on age and other comorbidities as 
well as their wishes. Microsatellite instability (MSI) testing of the tumour is also 
offered in people with CRC as it predicts treatment response. Depending on the 
type of treatment, intensive surveillance with colonoscopy may still be required, 
based on the BSG recommendations.(37)  
 
Table 2 Dukes staging of colorectal carcinoma and 5-year survival. (46,47) 
Stage Features 5-year survival 
A Tumour confided in the mucosa 95-100% 
B1 Tumour growth into muscularis propria 80-90% 
B2 Tumour growth through muscularis propria and serosa (full thickness) 80-90% 
C1 Tumour spread to 1-4 regional lymph nodes 
65% C2 Tumour spread to more than 4 regional lymph nodes 
D Distant metastasis (liver, lung, bones) 5-10% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
 
1.3 Modifiable lifestyle factors and CRC risk 
 
A number of modifiable lifestyle factors have been implicated to be related to 
CRC. It is estimated that 54% of CRC cases could have been prevented with 
lifestyle change.(48,49)  
Table 3 shows the preventability estimates of CRC in the UK for each lifestyle 
factor. Table 4 summarises the lifestyle factors that protect and increase risk of 
colorectal cancer.  
 
Table 3 Approximate percentage of preventable CRC cases in the UK according to lifestyle factors. (48,49) 
Lifestyle factor Approximate percentage of CRC 
cases preventable in the UK (%) 
Insufficient fibre consumption 28 
Processed and red meat 13 
Body fatness and obesity 11 
 
Table 4 Lifestyle protective and risk factors for colorectal cancer.   
Protective factors Risk factors 
Wholegrains Red & processed meat 
Dietary fibre Alcoholic drinks 
Weight loss Body fatness and weight increase 
 Smoking 
 
1.3.1 Diet and nutrition 
 
1.3.1.1 Red and processed meat 
 
Red meat is classified as a probable cause of colorectal cancer. Red meat 
contains high levels of haem iron, which has been proven to simulate 
endogenous formation of carcinogenic compounds, promoting CRC 
tumorigenesis. Furthermore, due to the high temperature of cooking, heterocyclic 
amines  and polycyclic aromatic hydrocarbons are formed, which promote 
carcinogenesis.(50–52) 
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The definition of “processed” generally describes meat that has been transformed 
to enhance flavour or preservation, through salting, curing, smoking and other 
processes. Types of processed meat include ham, bacon, salami, pastrami and 
some sausages.(50) Consumption of 50 grams of processed meat per day 
significantly increases the risk of CRC development by 16% (RR 1.16, 95% CI 
1.08-1.26), classifying it as a convincing cause. Processed meat can contribute 
to carcinogenesis in a similar mechanism to red meat. Moreover, the high fat 
content is a source of N-nitroso compounds and can also be responsible for the 
production of secondary bile acids, leading to tumorigenesis.(50,51,53)  
 
1.3.1.2 Wholegrains and dietary fibre 
 
Wholegrains or cereals are a category of energy stores of grain seed; the main 
types include heat, rice, barley, oats and rye. Wholegrain intake seems to be 
inversely correlated with colorectal cancer incidence. Per 90 grams of 
wholegrains per day, there was a significant 17% reduction in CRC risk (RR 0.83, 
95% CI 0.78-0.89), concluding that consumption of wholegrains might be a 
protective factor against CRC.(50,54,55) Wholegrains are rich in various 
bioactive components, such as Vitamin E, copper, zinc and selenium that contain 
anti-carcinogenic properties, which might account for the inverse relationship 
between wholegrain consumption and CRC development.(50,56) 
 
Dietary fibre is defined as undigested constituents of the plant cell wall and can 
be classified according to its source: cereal fibre, vegetable fibre and fruit 
fibre.(50) Various mechanisms have been proposed as protecting against CRC, 
such as the production of short-chain fatty acids with anti-proliferative effects and 
reduction in the intestinal transit time, resulting in reduced interaction of faecal 
mutagens with the colon mucosa. (54,57) 
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1.3.1.3 Alcoholic drinks 
 
Many studies have investigated the relation of alcohol to CRC risk, and WCRF 
data observed a significantly higher risk for CRC following alcohol consumption 
above 30 grams daily (RR 1.15, 95% CI 1.06-1.26), which is equivalent to 
approximately two drinks per day. This relationship is significant with increased 
alcohol intake and the findings are significant when also stratified by sex. The 
mechanisms of how alcohol (such as ethanol) increases CRC risk have been 
well-established. Ethanol is metabolised into acetaldehyde, which is toxic to 
tissues, including colonocytes. Increased consumption of ethanol can also lead 
to the production of reactive oxygen species, which can lead to DNA 
damage.(50,58) 
 
1.3.2 Body fatness and weight change  
 
Body fatness can be measured by proxys, such as Body Mass Index (BMI). A 
BMI of 18-24.9 is considered to be normal, above that it increases to overweight 
and obese. The dose-response meta-analysis from 38 studies conducted by 
WCRF concluded that there is a significant 5% increased risk of CRC per 5 kg/m2 
(RR 1.05, 95% CI 1.03-1.07). The association appears to be stronger above 27 
kg/m2, classifying greater body fatness or obesity as a convincing cause of CRC. 
This can be attributed to the fact that body fat releases insulin, resulting in 
increased cell growth and inhibition of apoptosis both in human and experimental 
studies.(50,59)  
 
Independent of body fatness, increase in weight is also associated with increased 
CRC risk. There is a 3% increased risk of CRC with a weight gain of 5kg and the 
association is stronger in men. Decrease in the weight through bariatric surgery 
has proven to decrease this risk by 27%.(60–62) 
 
1.3.3 Physical activity  
 
When comparing highest and lowest levels of physical activity, the former group 
showed a significant inverse association (RR 0.80, 95% CI 0.79-0.88), 
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decreasing the risk by 20%.(50) Increased physical activity results in reduction of 
insulin resistance and inflammation- both of which have been associated with 
tumorigenesis. Physical activity also stimulates digestion processes, reducing the 
transit time of faeces in the intestine; however, the evidence to support this in 
humans is limited.(63) Whether physical activity acts solely independently or 
whether the benefits are linked to loss of body fatness as well is not established.  
 
1.3.4 Smoking 
 
Smoking is a well-proven risk factor for many cancers, including CRC. A 
systematic review conducted 4 dose-response meta-analyses and showed 
significance associations with CRC risk, including daily cigarette consumption 
(RR = 1.38 for an increase of 40 cigarettes/day), duration (RR = 1.20 for an 
increase of 40 years of duration), pack-years (RR = 1.51 for an increase of 60 
pack-years) and age of initiation (RR = 0.96 for a delay of 10 years in smoking 
initiation).(64) From all the CRC cases in the UK, 7% are attributed to tobacco 
smoking. (49) 
 
1.4 Other CRC risk factors 
 
1.4.1 Socioeconomic status 
 
Socioeconomic status measures social, work and economic status, by measuring 
education, occupation and income respectively.(65) Deprivation can be 
measured differently, in Scotland the Scottish index of Multiple Deprivation, which 
encompasses education, employment, crime, housing and access to health 
services.(66) Low SES is considered a risk factor for CRC. The incidence of CRC 
is higher among males living in deprived areas in England. There is also higher 
mortality for males (30%) and females (15%) living in most deprived areas of 
England.(67) This trend can be attributed to the fact that behavioural risk factors, 
including poor diet, smoking and increased alcohol consumption are associated 
with deprivation. Even though awareness of the bowel screening programme is 
not affected, there is reduced screening uptake in these areas, with 66.6% uptake 
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in the least deprived compared to the 45.5% of the most deprived groups.(68,69) 
The decreased screening uptake can also partly explain the higher incidence.(69)  
 
1.4.2 Diabetes  
 
Diabetes has been implicated as a risk factor for many cancers.(70) CRC risk 
increases by around 30% in people with type II diabetes, according to meta-
analyses.(70–73) It has also been proven that diabetes is positively associated 
with increased CRC mortality (RR 1.20, 95%, CI: 1.03-1.40).(71,72) These data 
are consistent when stratified according to sex and geographical location.(74) 
Furthermore, meta-analyses have shown that metformin users may have 11% 
lower risk of CRC than non-users.(75)   
 
1.4.3 Inflammatory bowel disease 
 
Inflammatory bowel disease (IBD) is the collective term used to describe 
ulcerative colitis and Crohn’s disease. Due to the chronic inflammation of the 
bowel, a meta-analysis has shown that people with IBD have 70% higher risk of 
developing CRC compared to the general population.(76) The risk also increases 
with the extent and duration of IBD, as well as the location of the lesions.(76,77)  
 
1.4.4 Aspirin 
 
Aspirin has anti-inflammatory effects and some studies have shown aspirin to 
lower CRC risk by 32-49%.(78) In the meta-analyses of randomised control trials, 
aspirin has proven to be an effective chemopreventative agent, by reducing CRC 
risk by 17%.(79) The effects of aspirin may be more pronounced in people with 
higher BMI. This is because obesity is linked with increased inflammation thus, 
anti-inflammatory use might help in reducing this risk.(80) 
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1.5 Hereditary and Familial Colorectal cancer 
 
1.5.1 Familial Colorectal Cancer 
 
1.5.1.1 Background and aetiology  
 
Approximately 30% of all colorectal cancer cases are thought to have some 
familial component. (81,82) However, highly penetrant inherited mutations and 
well characterised clinical presentations can only account for about 5% of those 
cases. Thus, the aetiologies of the remaining familial CRCs are currently not 
completely understood.(83) Familial CRC, also known as non-syndromic, can be 
defined as CRC clustering in families, which cannot be associated with well-
known hereditary syndromes.  
 
A number of different factors may contribute to the increased risk observed in 
these families. It has been suggested that higher familial risk to CRC can be 
caused by inheritance of mutations in single genes that are less penetrant than 
the genes causing the hereditary syndromes, but which are simultaneously more 
common. Another hypothesis for the familial clustering is the inheritance of 
multiple polymorphisms that result in an additive effect, also known as polygenic 
inheritance.(83,84) Shared environmental exposure may also contribute to the 
higher cancer aggregation in families, as there are a lot of factors previously 
mentioned that can modify CRC risk. 
 
 1.5.1.2 Genome-wide association Studies (GWAS) 
 
There have been many genome-wide association studies that have identified 
common genetic risk loci for CRC.(85) A study that recruited 1,807 affected 
individuals and 5,511 controls found that variant rs6983267 on chromosome 
8q24 was significantly associated with CRC (odds ratio = 1.22; P = 4.4 × 
10−6).(86) Other studies have identified different single nucleotide polymorphisms 
(SNPs), also associated with increased risk, such as rs3802842 on 11q23 (OR = 
1.1; P = 5.8 × 10-10), rs7014346 on 8q24 (OR = 1.19; P = 8.6 × 10-26) and  
rs4939827 on 18q21 (OR = 1.2; P = 7.8 × 10-28).(87,88) The results from the 
studies have been evaluated in a systematic review and showed that the reported 
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variants on the reported loci are considered to be highly credible but also 
identified 23 less credible variants at 22 loci.(84,89)  Figure 5 shows some 
identified SNPs and the risk of CRC for each.  
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Figure 5 Summary description of meta-analysis of identified SNPs. Figure taken from source 85. 
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1.5.1.3 Risk classification 
 
Different studies have investigated the risk of colorectal cancer and adenomatous 
polyp development in familial clustering. These studies showed that there is a 
higher risk of polyp and cancer development compared to the general population, 
but lesser risk compared to the Lynch syndrome group (See Section 1.5.2). The 
personal risk is greater with increasing number of affected relatives and 
decreasing age of onset of those relatives.(90–92) A systematic review and meta-
analysis concluded that RR of CRC doubled for individuals with at least 1 FDR 
with CRC and almost tripled with two or more FDR’s. The RR also tripled when 
the relative was less than 50 years old at diagnosis, in contrast with people with 
a FDR more than 50 at time of CRC diagnosis, with a cumulative absolute risk 
estimate at age 85 of less than 5%.(92–94) Combining data from these studies, 
the BSG have classified patients with different family history of colorectal cancer 
into risk groups, presented in Table 5.(37) In the low-moderate groups, Lynch 
syndrome should not be excluded just on the basis of the Family History criteria, 
so immunohistochemistry (IHC) or microsatellite instability (MSI) testing should 
be carried out from pathology tumour material if available.  
 
Table 5 Risk stratification according to family history of colorectal cancer. Information taken from source 37. 
 
 
 
 
Risk group Family History Criteria 
Moderate-Low risk 
 
• Colorectal cancer in 1 FDR <50 years 
• Colorectal cancer I n 2 FDR ≥ 60 years old 
Moderate- High 
 
• Colorectal cancer in 3 FDR in first degree kinship, none <50 years 
• Colorectal cancer in 2 FDR in first degree kinship, mean age <60 
years 
Low risk • Other Family History of Colorectal Cancer 
First Degree Relative: FDR; first degree kinship: Affected relatives who are first-degree relatives of each other AND at least 
one is a first degree relative of the consultant. No affected relative <50 years old (otherwise high-risk criteria would apply). 
Combinations of 3 affected relatives in a first-degree kinship include: parent and aunt/uncle and/or grandparent; OR 2 
siblings/1 parent; OR 2 siblings/1offspring. Combinations of 2 affected relatives in a first-degree kinship include a parent 
and grandparent, or >2 siblings, or >2 children, or child + sibling. Where both parents are affected, these count as being 
within the first-degree kinship.(37) 
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1.5.2 Hereditary non-polyposis Colorectal cancer (HNPCC)- Lynch Syndrome 
 
1.5.2.1 Background and inheritance patterns  
 
HNPCC accounts for 3% of inherited CRC cases and is the most common 
inherited condition for CRC.(95) In the UK, an estimate of 1200 cases per annum 
of CRC are attributed to this condition.(96) The condition was described in the 
early 20th century, where families were identified with increased cases of CRC. 
These cases shared a number of clinical characteristics including early age, 
improved clinical outcome and involvement of the right colon. Histologically, the 
cancers more frequently are poorly differentiated and mucinous. They have a 
large number of tumour-infiltrating lymphocytes and a high level of microsatellite 
instability.(97) However, the term can be misleading due to the polyp formation 
extra-colonic cancers.(95,97,98) Malignancies involving the ovaries, 
endometrium, stomach, hepatobiliary epithelium, small bowel, uroepithelial 
epithelium and brain are associated with HNPCC.(99)  After colorectal cancer 
risk, the most common malignancy in HNPCC women is in the endometrium 
followed by the ovary with a lifetime risk of 27-71% and 3-14% respectively 
followed by the rest of the cancers (See Figure 6).(100–102) Henry Lynch 
elaborated the condition by marking the mode of inheritance and the tendency 
for the right colon; the condition was replaced with the term Lynch syndrome in 
cases linked with a germline pathogenic variant.(95,97,98) Lynch syndrome is 
inherited in an autosomal dominant manner, meaning that there is 50% chance 
of any child to inherit the disease if they have an affected parent.(95)  
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Figure 6 Lifetime risk of extra-colonic cancers associated with Lynch syndrome. Figure taken from source 102. 
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1.5.2.2 Associated genes 
 
The aetiology of HNPCC has been associated with changes in several genes 
(See Table 6).(103) These genes include the mismatch repair (MMR) genes, 
such as MLH1, MSH2, MSH6 and PMS2.(97) These genes encode proteins that 
are involved in DNA repair. Mutations in such genes results in a defective MMR 
mechanism, thus allowing errors in the DNA to be left unrepaired and increase 
substantially during the cell cycle. Accumulating errors result in abnormal function 
of the cells, increasing the risk for colon and other tumours.(104) MMR defects 
are associated with the molecular phenotype of Microsatellite Instability (MSI) in 
tumour DNA, defined as alternate sized repetitive DNA sequences that are not 
present in the corresponding germline DNA.(105) In Tayside, all colonic tumour 
pathology specimens are tested for MSI, as it is a hallmark of MMR defects. 
Nevertheless, the presence of an isolated MSI in tumour together with MLH 
mutation should be interpreted with caution, as promoter hypermethylation which 
results in MLH1 loss occurs frequently via epigenetic silencing, due to somatic 
mutations.(106)  
 
Another gene associated with Lynch syndrome is the EPCAM gene.(107) 
Although EPCAM gene is not directly involved with DNA repair, it lies next to the 
MSH2 gene on chromosome 2. Mutations in the EPCAM gene can cause 
hypermethylation of the promoter regions, resulting in decreased activity or 
complete deactivation of the MSH2 gene.(104) 
 
1.5.2.3 Increased risk  
 
There is an 80% lifetime risk of developing CRC with Lynch syndrome, with the 
average age of onset being less than 45 years; this varies according to specific 
mutations on different genes. The risk also varies between the two genders, with 
males having a greater risk of developing CRC than females.(37,108,109) In 
order to identify patients that might have inherited one of those genes, the 
Amsterdam I criteria were developed (See Section 1.6.1).(95) However, more 
than half of the cases were missed, leading to the revised Bethesda guidelines. 
When patients meet these criteria, they go on for further evaluation and genetic 
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testing. Another approach in identifying Lynch syndrome is tumour testing when 
Bethesda guidelines are identified.(106) This has proved to be cost effective and 
involved with testing for MSI and/or immunohistochemical analysis of CRC 
tumours.(110) Even though this analysis is very sensitive as approximately 90% 
of these cancers will have an MSI, the specificity is lower as 15% of sporadic 
CRCs are also MSI-H. IHC is conducted by utilising four antibodies specifically 
related to the MMR genes to evaluate tumours for MMR deficiency. Tumour 
testing can also be performed on endometrial cancers in order to effectively 
identify Lynch syndrome; tumour testing on other related tumours has not been 
evaluated.(83) Other models such as PREMM, MMRpro, and MMRpredict have 
also been developed and are discussed in Section 1.7. 
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Table 6 Summary table of HNPCC-associated genes. The table shows the genes associated with HNPCC, along with the percentage of cases attributed to each gene. It also shows the risk of 
developing HNPCC cancers when inheriting mutations from each. Information extracted from sources 104 and 109.  
 
 
Gene Chromosomal location 
Lynch cases 
attributed to 
the gene 
(%) 
Lifetime cancer risks 
Colon Endometrial Stomach Ovarian Small bowel 
Hepatobiliary 
tract 
Urinary 
tract 
MLH1 3p22.2 50% 
 
22-74%(males) 
 
22-53%(females) 
 
14-54% 0.2-13% 4-20% 4-12% 0.4-4% 0.2-25% 
MSH2 
 
2p21-p16.3 
 
40% 
 
22-74%(males) 
 
22-53%(females) 
 
40-60% 0.2-13% 4-20% 4-12% 0.4-4% 0.2-25% 
MSH6 
 
2p16.3 
 
7-10% 
 
22% (males) 
 
10% (females) 
 
16-26% 6-22% 22% 6-22% 6-22% 6-22% 
PMS2 
 
7p22.1 
 
<5% 
 
20% (males) 
 
15% (females) 
 
15% 6% 6% 6% 6% 6% 
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1.5.3 Familial adenomatous polyposis 
 
1.5.3.1 Background and inheritance pattern  
 
Familial adenomatous polyposis (FAP) is the second most common inherited disorder 
that increases CRC risk, with prevalence from 1 in 7000 to 1 in 22000 people, 
occurring most commonly in the western countries.(95,111,112) The condition was 
increasingly reported in the 1900’s, describing multiple polyp formation which occurred 
in autosomal dominant pattern; the adenoma to carcinoma progression was later on 
confirmed. FAP is the most clearly defined inherited colon cancer; it is characterised 
by the development of multiple adenomatous polyps (>100) in the colon and rectum, 
after the first decade of life. Furthermore, polyps might appear in the upper GI tract 
such as in the stomach and duodenum. The condition is associated with extraintestinal 
features as well, such as osteomas, epidermoid cysts, desmoid tumour formation, 
supernumerary teeth and Congenital hypertrophy of retinal pigment epithelium 
(CHRPE). Other tumours may also arise, such as hepatoblastoma and brain tumours, 
most commonly medulloblastoma.(95) The risk of developing adenomas is around 
90%, with a median age of 16 years old.(95,113) This risk rises steeply with age, with 
manifestation of adenomas at 10 years being 15%, rising to 75% by the age of 20 and 
to 90% by the age of 30.(113,114) Without surveillance and intervention, APC 
mutation carriers will develop CRC by the fourth decade of their life.(95,113) 
Surveillance is vital for the early detection of colonic polyps in order to prevent CRC 
with colectomy.(37,95,115) 
 
1.5.3.2 Associated genes 
 
Mutations on the Adenomatous Polyposis Coli (APC) gene, located on chromosome 
5q21 are responsible for FAP.(116) APC is a tumour suppressor gene and codes for 
APC protein that is important for cell adhesion and signal transduction. An example is 
the role of APC in the signalling of beta-catenin break-down when it is not 
needed.(95,111) Beta-catenin helps control the expression of genes that promote 
proliferation and differentiation; thus, mutations in the APC genes would result in 
uncontrolled proliferation and differentiation due to defective APC signalling. More 
than 300 pathogenic mutations have been reported in APC primarily in the first half of 
 39 
 
the gene (codons 169 to 1393).(95,117,118) The identified mutations are insertions, 
deletions and nonsense variants that create premature stop or frameshift mutations 
that lead to truncated protein. The variant that dominates FAP pathogenicity is the 
deletion of AAAG in codon 1309, which occurs in 10% of the FAP patients.(119) 
Pathogenic variants of the APC gene result in approximately 90% chance of getting 
the disease; both in men and women.(95)  
 
1.5.3.3 Attenuated Adenomatous Polyposis  
 
AFAP is a variation of FAP which predisposes to an increased risk of CRC, however, 
with a lower number of adenomas (average 30) and with predominantly right sided 
polyps.(120) In contrast to FAP, adenomas begin to form in the late twenties and CRC 
risk is higher at a later stage, at an average age of 56.(118,121,122) The extra-colonic 
manifestations are similar to classic FAP with the absence of CHRPE lesions. A subset 
of APC pathogenic variants is associated of AFAP. Pathogenic variants at the 5’ end 
of the APC gene and exon 4 variants usually present with 2-500 polyps.(118,123) 
Moreover, exon 9 pathogenic alterations result in the formation of 150 adenomatous 
polyps or less and no upper GI manifestations. Region 3’ pathogenic variants lead to 
approximately 50 adenomas.(123)  
 
1.5.4 MUTYH-Associated polyposis 
 
MUTYH-Associated polyposis (MAP) is an autosomal recessive inherited syndrome, 
also characterised by the presence of adenomatous polyps in the colon, leading to an 
increased risk of CRC. The risk of CRC for MAP patients is lower than FAP, but still 
ranges from 35-75% throughout life.(95,124)  Clinically, MAP resembles attenuated 
FAP; however, patients with this inherited syndrome develop fewer adenomas than 
the ones with APC pathogenic mutations.(125–127) Colonic polyposis typically occurs 
by the age of 40, although it can emerge at earlier ages.(128) Furthermore, colonic 
cancers tend to be right sided and there seems to be better prognosis than sporadic 
CRC.(129) MAP is mostly associated with hyperplastic polyps (47%) and serrated 
adenomas.(130) Extra-intestinal features include different types of cancer, such as 
gastric, small intestinal, endometrial, breast, liver, ovarian, bladder and thyroid. Skin 
cancers have also been reported, including melanoma, squamous epithelial and basal 
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cell carcinomas. Non-cancerous features include lipomas, osteomas and desmoid 
tumours.(131,132) The incidence of the extracolonic manifestations is lower in 
patients with MAP relative to patients with FAP or Lynch.(129)  
 
The gene associated with MAP is MUTYH gene, also referred as the MYH gene. This 
gene was firstly identified in 2002 and its cytogenic location is 1p34.1.(133) The 
MUTYH gene codes for the enzyme MYH glycosylase which is involved in DNA repair. 
MYH glycolysis has a role in base excision repair, preventing G:C to T:A transversions 
caused by oxidative stress. The inheritance pattern of MAP is autosomal recessive, 
meaning that both copies of this gene need to be mutated. This results in non-
functional or low functioning MYH glycolysis, leading to impaired base excision repair 
mechanism. Subsequently, this leads to building up of mutations, leading to cell 
overgrowth and tumour mutations. The most common mutations associated with 
MUTYH gene are at position 179 (Tyr179Cys) and 396 (Gly396Asp).(133) Founder 
pathogenic variants, meaning mutations that occur in specific ethnicities, are assumed 
for MUTYH, such as Y179C and G396D which account for 70% of biallelic pathogenic 
variants of norther European MAP patients, P405L in Netherlands and E490X in 
India.(134–136) A study with 7225 individuals with colorectal adenoma reported a 
prevalence of 4% (95% CI, 3%-5%) and 7% (95%, CI 6%-8%) among patients with 
10-19 and 100 to 999 adenomas respectively for biallelic MUTYH pathogenic variants. 
This implied that mutations in this gene are able to cause disease in both homozygous 
or compound heterozygous forms.(95)  
 
1.5.5 Rare Colon Cancer Syndromes 
 
1.5.5.1 Juvenile polyposis syndrome (JPS) 
 
JPS is a disease, usually presenting in childhood or early adulthood, characterised by 
hamartomatous polyposis throughout the GI tract with predominating colorectal 
polyps.(137) It has an autosomal dominant inheritance pattern, with 75% of the cases 
being inherited from one affected parent and the remaining cases resulting from de 
novo mutations. The prevalence of JPS is one in 100 000 individuals.(95) JPS is 
diagnosed when someone meets one or more of the following criteria: more than five 
juvenile polyps of the colon or rectum, juvenile polyps in other parts of the GI tract, any 
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number of juvenile polyps and a positive family history of JPS.(138) Juvenile polyp is 
a specific type of hamartomatous polyp, based on histological appearance. Even 
though these polyps are benign, there is a 10 to 50% increased risk of people with 
JPS to develop cancer of the GI tract at some point in their lives.(139) Presentation 
usually comprises non-specific GI symptoms such as diarrhoea or GI tract 
haemorrhage. Patients may also have signs and symptoms of Hereditary 
haemorrhagic telangiectasia (HHT) such as arteriovenous malformations, digital 
clubbing and osteoarthropathy, suggesting an overlap of these two syndromes. 
Additionally, 15% of individuals with JPS present with other abnormalities such as cleft 
palate, polydactyly, intestinal malrotation and abnormalities in heart, brain, genitalia or 
urinary tract. JPS can be subdivided into three different types. The first one occurs in 
infancy, is the most severe form and is associated with the poorest outcomes and 
increased morbidity and mortality.(140) Symptoms include protein-losing enteropathy 
which results in severe diarrhoea, failure to thrive and cachexia.(139,141) The second 
type is Generalised JPS which is characterised by polyps developing throughout the 
GI tract, and the third type is called juvenile polyposis coli and affects solely the 
colon.(139)  
  
Mutations in BMPR1A and SMAD4 genes are responsible for JPS.(142,143) The 
BMPR1A is located at 10q23.2 and codes for the bone morphogenetic protein receptor 
1A.(143) This protein binds to a ligand, activating a protein complex called SMAD 
proteins which are then transported to the cell’s nucleus to regulate proliferation and 
the activity of other genes. Mutations in the BMPR1A gene produces an abnormally 
short, non-functional protein, unable to ligand and activate the SMAD complex, 
resulting in unregulated cell growth that can lead to polyp formation. More than 60 
pathogenic variants, including nonsense, frameshift, missense and splice-site variants 
of BMPR1A have been identified and account for 25-40% of JPS cases.(139,143,144) 
SMAD4 is located on the long arm of chromosome 18, at position 21.2 and is 
implicated in 15-60% of JPS cases.(137) SMAD4 acts both as a transcription factor 
and a tumour suppressor and it is part of the transforming growth factor beta (TGB-β) 
pathway which regulates cell proliferation. Apart from JPS, SMAD4 mutations have 
been implicated in some cancers and conditions such as HHT, hence the overlap with 
JPS.(142,145) Until today, 78 pathogenic variants that lead to JPS have been 
identified between exons 6 and 11.(95)  
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1.5.5.2 Peutz-Jeghers syndrome (PJS) 
 
PJS is an early onset autosomal dominant disorder, characterised by the development 
of both benign hamartomatous and adenomatous polyps in the GI tract and increased 
risk of multiple cancers.(146) Signs of PJS are small, dark coloured spots on the lips 
and inside the mouth, near the eyes and nostrils and around the anus. There is also 
increased development of polyps that can cause recurrent bowel obstructions, chronic 
bleeding and abdominal pain. PJS predisposes to an increased risk of GI tract 
cancers, as well as pancreas, cervix, ovary and breast.(95,146) The estimated 
prevalence is 1 in 25000 to 30 000 individuals with a cumulative risk of around 40% 
by the age of 65 for CRC.(147) 
 
Mutations in the STK11 gene result in most cases of inherited PJS syndrome. This 
gene is located at 19p13.3 and acts as a tumour suppressor gene, hindering 
uncontrolled growth and proliferation.(148) Studies have demonstrated the 
development of hamartomas in heterozygous STK11 knock-out mice without the 
inactivation of the wild type allele. This suggests that initial tumour development in 
PJS can occur with haploinsufficiency (STK11 +/-) due to loss of heterogeneity 
(LOH).(149)  More than 340 pathogenic variants have been associated with PJS, 
producing a short non-functional serine/threonine kinase 11 enzyme which impairs its 
function.(148) The mutations are mostly localised to regions that code for the kinase 
domain of the protein and include a variety of nonsense, frameshift, missense, splice-
site variants and large deletions.(150)  
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Table 7 Summary of inherited conditions that increase risk of CRC development. 
Syndrome Inheritance Genes Functions Phenotype Risk of 
CRC 
Frequency 
in CRC 
Non-polypotic syndromes 
HNPCC AD MLH1 
MSH2 
MSH6 
PMS2 
DNA mismatch repair 
 
Early onset CRC 
Increased risk of extracolonic cancers such as 
endometrial, ovarian, gastric 
50-80% 2-4% 
Polypotic, adenomatous 
FAP AD APC Cell adhesion and signal 
transduction 
 
100-1000 polyps 
Duodenal and bowel adenomas 
Upper gastrointestinal cancer risk 
100% 1% 
AFAP AD APC Cell adhesion and signal 
transduction 
 
Milder phenotype, 0-100 polyps 
Duodenal and bowel adenomas 
Upper gastrointestinal cancer risk 
75% 1% 
MAP AR MUTYH DNA base excision repair <100 polyps 
Serrated adenomas and hyperplastic polyps 
Colon cancer, rarely gastric cancer 
35-75% <1% 
Polypotic, hamartomatous 
JPS AD BMPR1A 
SMAD4 
Regulation of cell 
proliferation through 
TGB-β signalling 
Multiple polyps in colon and throughout 
gastrointestinal tract 
 
10-50% <1% 
PJS AD STK11 Tumour suppressor, 
proliferation control 
Small polyps in bowel, small intestine and 
stomach 
Oesophageal, gastric, small intestine, colon 
and pancreatic cancer 
40-70% <1% 
Autosomal Dominant (AD); Autosomal recessive (AR), Colorectal Cancer (CRC); Hereditary Non-Polyposis Colorectal Cancer (HNPCC); Familial adenomatous polyposis (FAP); Attenuated FAP (AFAP); 
MUTYH associated polyposis (MAP); Juvenile polyposis syndrome (JPS); Peutz-Jeghers syndrome (PJS) 
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1.6 Risk Assessment models  
 
A variety of models have been created in order to predict risk of carrying the 
pathogenic mutations related to Lynch syndrome. Even though all the models 
have the same purpose, they differ in terms of the variables used to predict the 
risk as well as the way that they were developed. In addition, each one has its 
own advantages and disadvantages, in terms of sensitivity, specificity, cost-
effectiveness and accessibility. However, the fact that different populations were 
used to validate these models might impact on their accuracy. Thus, when 
deciding which specific model to use, both the patient population that is being 
evaluated as well as the clinical setting must be taken into consideration.  
 
1.6.1 Amsterdam criteria 
 
In 1990, the International Collaborative Group meeting in Amsterdam developed 
a set of criteria in order to identify families likely to have Lynch syndrome, known 
as the Amsterdam criteria.(95) The criteria included having at least three relatives 
with CRC and meeting all of the following : one affected individual is a first degree 
relative of the other two; at least two successive generations are affected; at least 
one CRC is diagnosed before the age of 50 years; FAP should be excluded and 
tumours verified by pathological examination. However, these criteria were not 
sensitive enough as more than 50% of families with Lynch syndrome failed to 
meet these criteria.(151) Thus, Amsterdam criteria II were developed in 
1999.(152) These criteria had as core principles not to deviate largely from the 
initial criteria and focus on clinical aspects as genetic testing might not be 
accessible to all families. The criteria remained the same with the addition of a 
new criterion: at least three relatives should have an HNPCC-related cancer 
(CRC, endometrium, small bowel, ureter, renal or pelvis).(152) When the 
causative mutations were identified, these criteria were proven to be specific but 
not sensitive predictors of MMR gene carriers.(153) On further evaluation, 
families have been identified that do not fulfil the criteria but were diagnosed with 
HNPCC.(154) Nevertheless, these criteria are still categorised as level IV 
evidence, coming from expert committee reports.(37) Thus, Amsterdam II criteria 
can still be used as a clinical tool to identify families with risk to carry DNA MMR 
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gene mutations.(155) Since the absolute risk of CRC development with Lynch 
can rise up to 56% depending on the mutated gene, any presentation of CRC 
before the age of 50 should be investigated for a possible Lynch 
diagnosis.(37,95) It should also be noted that in around 20% of the families that 
meet the Amsterdam criteria and exhibit MSI or loss of DNA MMR gene, the 
germ-line mutation cannot be detected using current methodologies.(95)  
 
For very small families, modified Amsterdam criteria are applied, thus a person 
can be considered to be at risk of HNPCC with only two CRCs in FDR, in which 
one of the cancers was diagnosed before the age of 55. If two FDRs are affected 
by CRC, a third relative with an early onset HNPCC related cancer such as in the 
endometrium is sufficient for meeting the criteria. In patients with a very early 
onset of CRC diagnosis (before 40), with no FH, the patient is still considered to 
be at risk of having HNPCC.(156) 
 
1.6.2 Bethesda guidelines 
 
In 1997, the National Cancer Institute met in Bethesda in order to discuss 
identification of people with HNPCC.(106) This led to the development of a set of 
guidelines, aiming to categorise people with HNPCC that should be tested for 
MSI, as MSI accounts for approximately 15% of CRC.(95) The original guidelines 
included a panel of genes that were tested in order to identify MSI: BAT25, 
BAT26, D2S123, D5S246 and D17S250. However, these guidelines came with a 
set of limitations, so in 2002, another workshop was held in order to tackle issues 
that were identified and consider revision and improvement (See Table 8 for the 
revised guidelines).(106)  People identified as high-risk are then recommended 
to have molecular evaluation, either through MSI or IHC analysis of tumour 
followed by germline testing or directly through germline testing of mutations. At-
risk relatives should be given the option of genetic counselling and testing. If a 
mutation is not identified but clinical suspicion of HNPCC is high, then patients 
and their at-risk relatives should be counselled and commence surveillance.(106) 
Members of the workshop included Dr Henry Lynch and Dr Albert Warthin, who 
were the first who suspected and later on discovered this syndrome.(97) In order 
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to identify the sensitivity and specificity of the modified Bethesda guidelines, a 
study interviewed 127 CRC patients who were considered to be high-risk based 
on these guidelines. The investigators reviewed their medical records as well as 
the performed MSI analysis of tumours. From the 127 patients, 42% of those 
were found to have MSI-H tumours. Interestingly, 36 patients were tested for 
mutations with 61% of them testing positive. Significant predictors of MSI were 
early age of CRC diagnosis, number of CRC per family and presence of other 
HNPCC cancers in the family. Presence of multiple cancers in a single-family 
member was a specific predictor of MSI status, regardless of age.(157) Further 
studies revealed that these guidelines are 96% sensitive for identifying MSI-H 
tumours in high risk populations, however, their specificity is relatively low 
(27%).(158) Nevertheless, the aim of the guidelines is not to identify MSI tumours 
from patients in the general population, but HNPCC patients. This means 
including MSH2 and MLH1 mutation carriers. When investigating specificity and 
sensitivity of these criteria in MSH2 and MLH1 mutation carriers, the Bethesda 
guidelines were found to be the most sensitive but the least specific compared to 
the existing criteria (Amsterdam I, II and modified Amsterdam criteria).(159) 
These guidelines have also proven to be highly cost-effective when identifying 
HNPCC.(95,106) 
 
 
Table 8 Revised Bethesda Guidelines. Information extracted from source 106.  
The Revised Bethesda Guidelines for testing colorectal cancer tumours for 
MSI 
1. CRC diagnosed in a patient who is less than 50 years of age 
2. Presence of synchronous, metachronous colorectal or other HNPCC-
associated tumours*, regardless of age 
3. Colorectal cancer with the MSI-H histology diagnosed in a patient who 
is less than 60 years of age 
4. Colorectal cancer diagnosed in one or more FDR with HNPCC- related 
tumour with one of the cancers being diagnosed under the age of 50. 
5. Colorectal cancer diagnosed in two or more FDR or SDR with HNPCC-
related tumours, regardless of age. 
*CRC, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, 
biliary tract and glioblastoma of the brain, sebaceous gland adenomas and 
keratoacanthomas and carcinoma of the small bowel.  
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1.6.3 PRediction model for gene mutations (PREMM) 
 
The PREMM1 model is a clinical prediction algorithm that was introduced in 2006 
and predicts the probability of carrying MLH1 and MSH2 gene mutations. Later 
on, PREMM1,2 calculator provided the cumulative probability of carrying either of 
these two mutations. The PREMM1,2,6 model was introduced in 2011, replacing 
the previous two models as it incorporated their algorithms along with the 
cumulative probability of identifying MSH6.(160) The most recent development of 
PREMM5 in 2017 includes PMS2 or EPCAM gene mutations too.(161) In order 
to evaluate risk, the model requires personal or family history of CRC, 
endometrial or other Lynch syndrome-associated cancers. It also includes 
specific types of cancer and ages at diagnosis of both first- and second-degree 
relatives from the affected side of the family.(161,162) Advantages of this model 
is the fact that it is easily accessible via the web and it is simple in its use. It has 
also been validated with a cohort of 1058 patients with CRC and includes a broad 
spectrum of extra-colonic cancers.(162) Even though the risk prediction model 
includes first- and second-degree relatives, it does not take into account family 
size and thus may overestimate the risk in some cases.(95,163)  
 
1.6.4 MMRpro 
 
MMRpro is another statistical model which was developed to assess the 
probability of carrying MLH1, MSH2 and MSH6, based on family history of CRC 
and endometrial cancer.(164) A major disadvantage is the fact that it does not 
include PMS2 and EPCAM. Moreover, its use is restricted to specialists due to 
its limited access. It has been also deemed as more time consuming relative to 
other models as it requires data from an individual’s entire pedigree.(163–165)   
 
1.6.5 MMRpredict 
 
MMRpredict also uses a statistical model to identify patients with mismatch repair 
gene mutations. The criteria used are age, gender, location of tumour, personal 
history of CRC and other cancers, family history of CRC and other cancers.(166) 
However, this model has been found to be less accurate as the model was 
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developed only by using CRC patients of less than 55 years of age and did not 
include extracolonic malignancy.(164)  
 
1.6.6 Polygenic risk and personalised screening 
 
A number of studies have attempted to personalise the screening strategy of CRC 
by using FH data as well as polygenic risk scores (PRS).(167–169) The latter 
refers to known SNPs, identified in GWAS studies that have proven to increase 
the risk of CRC development.(170) There is an increasing number of SNPs 
associated with CRC, and although the risk associated with each SNP is small, 
combination of multiple SNPs in genetic risk scores may be clinically relevant and 
allow more targeted CRC prevention and early detection.(167) However, the 
cost-effectiveness of this type of screening is not yet known and further 
comparative studies between PRS and current guidelines are required before 
clinical utilisation.  
 
1.7 Guidelines and Surveillance Recommendations  
 
1.7.1 Moderate risk family history 
 
Since there is an increased risk of polyp and cancer development in people with 
non-syndromic familial CRC, increased surveillance is recommended to minimise 
this risk through colonoscopic screening and adequate polypectomy. Studies 
comparing familial colorectal cancer in families with and without Lynch syndrome 
has shown that the risk of polyps and cancer is lower in people without Lynch 
syndrome.(91,171–174) They have also identified that people under the age of 
45-50 years may not require any surveillance if there is not an extensive family 
history of CRC and three yearly colonoscopies in people with an extended family 
history.(171,172,174)  
 
Based on these studies, different countries have given recommendations on 
surveillance guidelines.(37,175) Currently, there are no guidelines issued by the 
National Institute of Health and Care excellence (NICE), but the BSG have 
published their recommendations based on these studies and expert opinion, 
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which are also utilised by Scottish Intercollegiate Guidelines Network 
(SIGN).(176) For low-moderate risk patients (as classified by the BSG), the 
recommendation is once only colonoscopy at 55 years of age with no follow-up if 
this is normal. For people in the high-moderate group, BSG recommends 
colonoscopic surveillance to start at age 50, and repeat every five years until the 
age of 75.(37) Standard surveillance guidelines will be used if the colonoscopy is 
abnormal, for example adenomatous polyp detection (See Section 1.2).  These 
guidelines fail to include patients with extensive family history of high-risk 
adenomas without a clinical and family history of polyposis conditions. In contrast, 
the US multi-society task force on colorectal cancer includes guidelines on people 
that have relatives with advanced adenoma, depending on number of polyps and 
age of relatives. In general, these guidelines recommend screening at an earlier 
age, for example if a person has a FH of CRC or a FDR with advanced adenoma 
age <60 or 2 FDR with CRC at any age, the recommended surveillance is 
colonoscopy every 5 years beginning 10 years before the age of diagnosis of the 
youngest relative or age 40, based on whichever is earlier. They also include 
recommendations for people with a single FDR with CRC diagnosis ≥60, again 
starting screening at age 40.(175)  
 
1.7.2 Lynch syndrome  
 
Compared to moderate risk groups, people with Lynch syndrome have a higher 
risk of cancer and adenomatous polyp development. These has been shown in 
many studies, with a 1 in 5 and a 1 in 13 risk in males and females respectively 
to develop CRC if they fulfil Lynch syndrome criteria. Most studies recommend 
that the ideal surveillance time would be every one or two years, depending on 
the study.(91,172,174,177)  For people at risk of HNPCC that fulfil the modified 
Amsterdam criteria or they are an untested FDR of a proven mutation carrier or 
they are an MMR gene carrier, colonoscopy is advised from age 25, every 18-24 
months, as well as upper gastrointestinal endoscopy of the oesophagus, stomach  
and duodenum (OGD) from the age of 50, every two years. People with 1 FDR 
with MSI-H CRC and IHC loss of MSH2, MSH6 or PMS2 expression, 
colonoscopic surveillance is also advised to start at 25 years of age and be 
repeated every two years with two-yearly OGD starting at 50 years old.(37) As 
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mentioned, MSI-H CRC with IHC loss of MLH1 is excluded in elderly patients with 
right sided tumours as it is usually a somatic epigenetic event.(37) Surveillance 
would also continue in the event of partial colectomy, usually with two yearly 
sigmoidoscopies.  
 
1.7.3 FAP 
 
Due to the high risk of carcinoma development in an early age, FAP are strongly 
advised to have a procto-colectomy and pouch or colectomy before the age of 
30.  In patients at risk of FAP but without an identified mutation, colonoscopy or 
alternating colonoscopy with flexible sigmoidoscopy should be commenced at 
puberty with annual screening until the age of 30 and thereafter 3-5 years until 
60 years. Procto-colectomy or colectomy is favourable if the patient is clinically 
positive. If the person fulfils the FAP criteria or is a proven APC mutation carrier 
opting for a deferred prophylactic surgery, colonoscopy or alternating 
colonoscopy with flexible sigmoidoscopy as well as OGD is recommended to start 
at diagnosis or puberty twice a year.(37) Puberty is loosely defined to allow a 
flexible approach, depending on the level of maturity of the individual. The 
guidelines also do not differentiate between FAP and AFAP, in which the latter 
has a much later age of colorectal cancer incidence risk, as well as fewer number 
of polyps developing. Patients after colectomy and or ileorectal anastomosis are 
still advised to be screening with annual flexible or rigid rectoscopy or pouch 
endoscopy (depending on the procedure) as well as OGD every three years. This 
is because studies have shown risk of rectal cancer to be around 20% after total 
colectomy.(178,179) Screening recommendations for other extra-colonic cancers 
are beyond the scope of this study and can be accessed through different 
guidelines.(180)  
 
1.7.4 Other High-risk categories 
 
People with MAP are recommended to have colonoscopic screening starting from 
age 25 biennially and OGD from age 30, 3-5 yearly.(37) Similarly, to FAP, 
mutation carriers should be individually counselled for prophylactic surgery 
options. The European society of medical oncology (ESMO) also has similar 
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recommendations.(180) For PJS, the colonoscopic advice is the same as MAP, 
but also there is an additional screening of small bowel video capsule endoscopy 
(VSE) or MRI every 2 to 4 years. Screening for stomach cancer is also different, 
with OGD starting at age 25 and repeating every two years.(37) The National 
Comprehensive cancer network (NCCN) has similar guidance for PJS, whereas 
ESMO guidelines recommend the first colonoscopy at age 8 and the second at 
age 18 if the findings of the initial screening are normal.(37,180,181)   
 
1.8 Basis of this research 
 
The above findings clearly demonstrate the demand for the development of a 
revised risk model which is both sensitive and specific in identifying familial CRC 
in the clinical setting. According to stratified risk, this model should provide more 
information regarding the management of these patients and the screening 
recommendations.  
 
The BSG guidelines recommend an audit regarding people attending the service 
who are concerned about their risk of CRC with outcomes including extent of 
family history, assignment of risk, and surveillance prevalence of cancer, 
adenomas as well as morbidity and mortality. To our knowledge, no one has 
attempted to validate the effectiveness of BSG guidelines, which are also 
recommended by the SIGN guidelines, in a patient cohort who have attended 
clinical genetics regarding their risk. In Tayside, it is feasible to analyse a large 
retrospective cohort of people who have attended clinical genetics and determine 
their BSG risk category and outcomes over a period of time. This pilot study aims 
to assess the effectiveness of risk stratification of the BSG guidelines and 
evaluate the recommended colonoscopic surveillance in the Tayside cohort, as 
well as demonstrate the methodology which could be used to conduct similar 
studies in other centres.  
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Chapter 2: Aims and objectives 
 
2.1 Aims 
 
The aims of this study are: 
 
• To examine how effective the BSG guidelines for familial colorectal cancer 
are at identifying people at increased risk of colorectal cancer 
• To identify which elements of family history, appear to predict an increased 
risk of colorectal cancer 
• To investigate the relative and absolute risks of developing colorectal 
cancer depending on the risk category in the Tayside cohort 
• To explore whether people with increased risk of CRC also have an 
increased relative and absolute risks of having adenomatous polyps being 
detected  
• To evaluate whether guidelines identify people who will benefit from 
increased screening 
 
2.2 Objectives  
 
In order to achieve the above aims, the following objectives will be carried out: 
 
• A cohort of patients who have attended the clinical genetics regarding risk 
of colorectal cancer will be identified and assigned to a risk category 
depending on BSG criteria. Those who subsequently develop colorectal 
cancer or have adenomatous polyps detected will be identified.  
• Based on the collected information, risk of colorectal cancer and polyp risk 
for people in each category will be calculated.  
• Statistical analysis will be performed to assess if any particular element of 
FH is significantly related to colorectal cancer risk.  
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Chapter 3: Methods 
 
3.1 Approvals and data collection 
 
3.1.1 Approval 
 
NHS Tayside Caldicott approval (See Appendix 1) was obtained, to collect data 
concerning the cohort of patients that attended the clinical genetics department 
with a family history of colorectal cancer between 2000 and 2009 inclusive. The 
aim was to assess and assign their risk of CRC according to BSG guidelines and 
subsequently identify the patients that developed CRC by following them up to 
the end of 2018. The approval authorized the use of the clinical genetics database 
to collect the relevant family history and genetic data, the endoscopic database 
for the follow-up of the patients and outcomes of colonoscopies, as well as the 
pathology database for polyp and cancer histopathology results. Since there was 
no patient contact for this study, ethics committee approval was not required.  
 
3.1.2 Inclusion and Exclusion Criteria 
 
This was a longitudinal study, with a retrospective patient cohort. Any individual 
referred to genetic counselling regarding FH of CRC from 2000-2009 was 
included in the study, regardless of age and gender. Patients were excluded if 
the available personal and FH information were more than 50% incomplete. 
Additional exclusion criteria include patients with a personal history of CRC or 
previous colectomy of any kind (total, subtotal etc). Furthermore, patients that 
tested negative for the known familial mutation were excluded in the study as 
they are considered to be at population risk.  
 
3.1.3 Data collection and handling 
Patients who met the inclusion criteria were identified and their FH information 
was collected from clinical genetics electronic records at Ninewells hospital and 
medical school, NHS Tayside. The data were extracted from clinical pedigrees, 
notes, FH questionnaires, as well as official correspondence to or from the clinical 
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genetics department (See Table 9 for a comprehensive list of the clinical 
variables collected). If available, cancer data were extracted from the information 
services division Scotland. Any genetic testing on the patient or family member 
relating to a familial CRC condition was also identified through the genetics 
database. These included mutations identified through blood or specimen DNA 
testing.  
Table 9 List of clinical variables collected. 
Patient 
Information 
Community Health Index Number (CHI Number) 
Date of Birth, Date of Death (if applicable) 
Pedigree number 
Date of first appointment in clinical genetics 
Age at first appointment in Clinical Genetics 
Any cancer diagnosis (type), Age of cancer diagnosis 
History in first-
degree relatives 
(FDRs) 
For mother and father: 
Any cancer diagnosis(type), age of cancer diagnosis 
 
For sister(s)/brother(s): 
Total number of sisters/brothers, number of half-sisters/half-
brothers 
Any cancer diagnosis (type), age of cancer diagnosis 
 
For daughter(s)/son(s) 
Total number of daughter(s)/son(s) 
Any cancer diagnosis (type), age of cancer diagnosis 
 
History in second-
degree relatives 
(SDR’s) 
Number of total SDRs 
Any cancer diagnosis (type), age of cancer diagnosis 
Whether SDR is paternal or maternal relative 
Mutation testing 
Mutation testing in patient (YES/NO) 
Relative with mutation testing (YES/NO) 
Type of mutation testing (blood/pathology specimen) 
Which mutations tested 
Mutation result (positive/negative) and if positive, which 
mutation 
Endoscopic data 
Year of endoscopy (colonoscopy) 
Outcome of endoscopy (polyp/no polyp/cancer) 
Risk of polyp (according to BSG criteria)- number, size 
Excision of polyp (yes/no/partly) 
Pathology data 
Polyp/cancer biopsy 
Polyp/cancer result of biopsy (adenoma/hyperplastic/other) 
Surgical data 
Any type of colectomy (yes/no) 
Year of colectomy 
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People within the cohort who were followed up by colonoscopy were identified 
through the endoscopy databases and Clinical Portal from years 2000 to 2018 
inclusive within NHS Tayside. Data collected included the year of colonoscopy 
as well as colonoscopic findings, limited to normal, polyps and cancer. 
Information on polyps included the number of polyps and the size to assign a risk 
category (Low, Intermediate or High) according to BSG criteria, as well as if all, 
some or no polyps were extracted and retrieved. The histopathology of any 
polyps retrieved (Adenomas, Tubular adenomas, Tubulovillous adenomas, 
Hyperplastic polyp) and cancer pathology was identified through the pathology 
database. 
All the patient identifiable information was stored in a secure disk on a Ninewells 
Hospital computer network in NHS Tayside. For safe handling of data out with 
this setting, community health index (CHI) number, date of birth and pedigree 
number were removed, and a study identification number was assigned to each 
patient. The pseudo-anonymised data were stored in a password protected file 
on a password protected laptop.  
3.2 Assigning BSG Risk category 
 
3.2.1 HNPCC  
 
All people included in the study were assigned de novo into their corresponding 
risk categories according to BSG criteria based on FH information. All 
subcategories of FH that are included in each risk category can be seen in Table 
10. Categories included low, moderate-low, moderate-high and high-risk. High-
risk patients were subdivided into the ones with a confirmed identified mutation 
and the ones with high-risk FH but without an identifiable mutation. People who 
did not meet high risk FH criteria but had a confirmed mutation were allocated in 
high-risk category. A family member with two colorectal cancers or two different 
HNPCC associated cancers was counted as two individuals.  
A panel of experts comprising of a consultant clinical geneticist and genetic 
counsellor discussed any patients that did not meet specific FH of BSG 
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categories. These patients were assigned to risk categories according to FH 
information and clinical judgement.  
Table 10 BSG risk categories and Family history criteria. Information extracted from source 37. 
BSG Risk Category Fulfilled criteria for each category 
 
High risk 
 
• Confirmed mutation carrier 
• Fulfils Amsterdam Criteria  
• Untested FDR of proven mutation 
carrier 
• 1 FDR with MSI-H colorectal cancer 
AND IHC shows loss of MSH2, 
MSH6 or PMS2 expression. 
 
 
Moderate- High risk 
 
 
 
 
Moderate-Low risk 
 
 
• Colorectal cancer in 3 FDR in first 
degree kinship, none <50 years 
• Colorectal cancer in 2 FDR in first 
degree kinship, mean age <60 years 
 
• Colorectal cancer in 1 FDR <50 years 
• Colorectal cancer in 2 FDR in first 
degree kinship, mean age ≥ 60 years 
 
 
Low risk 
 
• Other Family History of Colorectal 
Cancer 
 
 
 
3.2.2 Polyposis conditions 
 
Patients with multiple polyps and suspected polyposis conditions were placed 
into their respective condition category. Patients with familial adenomatous 
polyposis (FAP) were dividing into at risk FAP if they were a member of an FAP 
family with no mutation identified or at high risk if they fulfilled the clinical criteria 
of FAP or were proven APC mutation carriers. Any FAP patients that underwent 
colectomy prior to referral were excluded from the study.  
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3.2.3 Polyps 
 
For the identification of adenomatous polyps during surveillance, risk categories 
were assigned according to BSG adenoma surveillance. Low, Intermediate and 
High risk were assigned according to the number and size of adenomatous 
polyps as per BSG guidelines (See Table 1). Surveillance time may have been 
modified from that proposed by the guidelines according to polyps and FH.  
 
3.3 Mutation carriers 
 
3.3.1 HNPCC 
People with HNPCC associated mutations within the cohort were identified. In 
cases where family history would have placed them into a low or a moderate-risk 
group, a confirmed mutation would mean that these patients fall into the high-risk 
category, as per guidelines. People with confirmed mutations that were assigned 
as variants of uncertain significance (VUS), according to American College of 
Medical Genetics and Genomics (ACMG) were assigned to a category according 
to FH criteria.  
3.3.2 Polyposis 
People who tested positive for mutations for FAP and attenuated familial 
adenomatous polyposis were assigned to a separate high-risk category. Patients 
that were FDR of a known mutation carrier were put into high risk category, even 
if they were not tested themselves. Similarly, patients were assigned to be at risk 
if there was clinical evidence (i.e. multiple polyps on colonoscopy) of FAP or 
AFAP even if a mutation was not found on testing. A few other mutations 
predisposing to polyposis conditions were identified in the cohort. These were 
assigned a high-risk, but no further analysis was performed as the statistical 
power would not be sufficient to reliably detect significant differences.  
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3.4 Polyps and cancer 
People who were followed up through colonoscopic screening were identified as 
described in Section 3.1.1. Subsequently, those that developed polyps were also 
assigned a polyp risk category, according to BSG criteria (See Section 3.2.3 and 
Table 1). Additionally, information was collected if polyps were excised or not. 
Analysis was performed on patients developing adenomatous polyps as these 
are regarded as cancer precursor lesions and they have a high risk of developing 
into an adenocarcinoma if left unexcised. The number of people in the cohort who 
also developed adenocarcinoma were identified as previously described and 
analysis was performed to determine the risk of developing adenocarcinoma in 
each risk category. 
3.5 Statistical analysis 
 
Relative Risk (RR), Odds Ratio (OR), Positive Predictive Value (PPV), Negative 
Predictive Value (NPV) and incidence were calculated, using the low-risk cohort 
as a reference group. SPSS statistics software and Microsoft Excel were used 
for data analyses. For analyses generating a significance value (p-value), p≤0.05 
was used to determine significance.  
 
3.5.1 Percentage 10-year absolute risk calculation 
A % 10-year absolute risk for people within the cohort for each BSG risk category 
as well as HNPCC mutation carriers was calculated. This was performed for risk 
for the age groups 0-49 and above 50. The number of years follow-up between 
those age ranges was added to get the people years of follow-up. The % 
incidence of CRC per person year of follow up in both the age categories was 
calculated and multiplied by 10 to give the approximate 10-year risk for that age 
range. Similarly, the % incidence of adenomatous polyps per person per year of 
follow-up and the 10-year absolute risk for the age ranges was calculated. A % 
5-year absolute risk was not calculated due to the limited cohort size.  
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3.5.2 Chi-square test, Fischer’s exact test, independent t-test and one-way 
analysis of variance (ANOVA) 
In order to calculate categorical variables such as cancer development (yes/no), 
Pearson’s chi-squared test was used when numbers were sufficient or Fischer’s 
exact test to report the asymptomatic two-sided p-value. The categorical 
variables analysed against cancer development is shown in Table 11. 
To compare continuous variables (See Table 11), independent t-test was used. 
Levene’s test was used to screen whether the data were normally distributed. 
Where Levene’s test was significant, the reported p-value (2-sided) for the 
independent T-test does not assume equal variance of the continuous data. 
These variables were selected as broad descriptors for the family history of 
cancer. 
To analyse the means of continuous variables with more than two groups for 
significance, an omnibus one-way analysis of variance (ANOVA) was performed. 
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Table 11 Categorical and continuous variables for Chi-squared and t-test analysis respectively.  
Categorical variables analysed in Chi-
Squared analysis 
Continuous variables analysed in Independent 
T-test analysis 
1 affected FDR or SDR with CRC cancer 
 
≥ 2 affected FDR or SDR with CRC cancer 
 
≥ 3 affected FDR or SDR with CRC cancer 
 
Parent affected with CRC 
 
Sibling affected with CRC 
 
Average age of relatives at diagnosis with CRC 
<50 
 
Average age of relatives at CRC diagnosis <60 
 
Proportion of FDRs and SDRs affected with CRC 
 
Average age of all relatives at CRC diagnosis 
 
Proportion of FDRs affected with CRC 
 
Average age of FDRs at CRC diagnosis 
 
Proportion of SDRs affected with CRC 
 
Average age of SDRs with CRC diagnosis 
 
 
 
 
1 affected FDR or SDR with HNPCC associated 
cancer 
 
≥ 2 affected FDR or SDR with HNPCC associated 
cancer 
 
≥ 3 affected FDR or SDR with HNPCC associated 
cancer 
 
Parent affected with HNPCC associated cancer 
 
Sibling affected with HNPCC associated cancer 
 
Average age of relative at diagnosis with HNPCC 
cancer <50 
 
Average age of relatives at HNPCC cancer 
diagnosis <60 
 
 
 
 
Proportion of FDRs and SDRs affected with HNPCC cancer 
 
Average age of all relatives at HNPCC diagnosis 
 
Proportion of FDRs affected with HNPCC cancer 
 
Average age of FDRs at HNPCC diagnosis 
 
Proportion of SDRs affected with HNPCC cancer 
 
Average age of SDRs at HNPCC diagnosis 
 
1 affected FDR or SDR with CRC or HNPCC 
cancer 
 
≥ 2 affected FDR or SDR with CRC or HNPCC 
cancer 
 
≥ 3 affected FDR or SDR with CRC or HNPCC 
cancer 
 
Parent affected with CRC or HNPCC cancer 
 
Sibling affected with CRC or HNPCC cancer 
 
Average age of relatives at diagnosis with CRC or 
HNPCC cancer <50 
 
Average age of relatives at CRC or HNPCC 
diagnosis <60 
 
 
Proportion of FDRs and SDRs affected with CRC and 
HNPCC 
 
Average age of all relatives at CRC and HNPCC diagnosis 
 
Proportion of FDRs affected with CRC and HNPCC 
 
Average age of FDRs at CRC and HNPCC diagnosis 
 
Proportion of SDRs affected with CRC and HNPCC 
 
Average age of SDRs at CRC and HNPCC diagnosis 
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3.5.3 Kaplan-Meier survival analysis 
 
KM survival analysis was used to asses both adenocarcinoma and adenomatous 
polyp detection across the different BSG risk categories. Time was measured in 
number of years of follow-up for each risk category and the patients were 
censored at death or colectomy. Endpoints included CRC or first adenomatous 
polyp development depending on the KM curve and the end of the follow-up, the 
latest being the end of 2018. Separate analyses were performed to compare each 
BSG risk category for cancer or polyp development. Two separate analyses were 
conducted for the high-risk group, both including and excluding mutation carriers. 
For the survival curves looking at polyp detection, age-dependent analysis was 
also performed, for ages 0-49 and ≥50 years. KM survival curves were generated 
and presented for selected sets of results.  
 
3.6 Sample size calculation 
In order to address whether the study was adequately powered, a retrospective 
sample size calculation was performed on the categorical data: i.e. CRC 
incidence. To do so, the methodology from Jones, Carley and Harrison was used 
for studies reporting categorical data, i.e. Diagnosis of CRC.(182) The reason for 
performing the power calculation retrospectively was that when the study was 
initiated, the number of available patients was unknown and therefore not 
possible to ascertain power. The following assumptions were made when 
calculating the sample size: 
• BSG guidelines do not effectively distinguish between medium and high-risk 
groups of familial CRC. 
• Type 1 error is to be avoided at the conventional level of .05 (pα). 
• Type 2 error is to be avoided at the conventional level of .8 (pβ). 
• The clinically important difference to be detected is the difference in % 
absolute risk between the risk categories. 
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The following risk levels were used: 
• Population risk was calculated using invasive colorectal cancer rates per 
100,000 reported for the year of 2017; the data is available to download from 
ISD Scotland.(183) The lifetime rate per 100,000 per year of developing CRC 
is 69.6. This equates to 0.07% per person lifetime risk.  
• For the moderate risk group, BSG guidelines find the risk of CRC to be 
between 1 in 6-10, depending on different studies.(37) 1 in 6 was used as the 
risk for the calculation so that the sample size needed to detect the smallest 
possible difference could be calculated. 
• For high risk groups, there is 1 in 5-13 risk of developing CRC, depending on 
gender.(37) 1 in 5 was used as the risk for the calculation so that sample size 
needed to detect the smallest possible difference could be calculated. 
Firstly, the standardised difference between the proportions of expected CRC 
was calculated: 
Standardised difference= p1-p2/√(P (1- P) ) 
p1 = risk of colorectal cancer in higher risk group 
p2 = risk of colorectal cancer in lower risk group 
P= (p1+ p2)/2 
To work out the required sample size, a standardised risk is used and applied to 
the nomogram below shown in Figure 7. A line is drawn from the calculated 
standard difference across to the designated pβ and by looking at the pα level 
of 0.05, the required sample size can be deduced.  
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Figure 7 Nomogram for the calculation of sample size. Figure taken from source 182. 
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The results of the retrospective power calculations are as follows:  
3.6.1 Sample size required to detect clinically significant difference between 
population and moderate risk group 
 
Standardised difference= p1-p2/√(P (1- P) ) 
p1=minimum risk of CRC in moderate risk group = 0.17 or 17% 
p2 = population risk of CRC=0.07 or 7% 
 
P = (p1+p2)/2 
 
P = (0.17 + 0.07)/2		= 0.12 
 
Standardised difference= (0.17 − 0.07)/,0.12	(1 − 0.12)	
 
Standardised difference= 0.1/√0.1056 
 
Standardised difference= 0.1/0.325 
	
Standardised difference= 0.308 
 
Using the above nomogram, a standardised difference of 0.308 with a pβ of 0.8 
and pα of 0.05, a sample size of 300 subjects is required to adequately power the 
study. There were 288 low and 316 moderate-risk subjects (604 in total) in the 
study cohort, meaning that the study is adequately powered to detect a clinical 
difference between low and moderate risk groups.  
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3.6.2 Sample size required to detect clinically significant difference between 
population and high-risk group 
 
Standardised difference= p1-p2/√(P (1- P) ) 
p1=minimum risk of CRC in high risk group = 0.2 or 20% 
p2 = population risk of CRC=0.07 or 7% 
 
P = (p1+p2)/2 
 
P = (0.2 + 0.07)/2		= 0.135 
 
Standardised difference= (0.2 − 0.07)/,0.135	(1 − 0.135)	
 
Standardised difference= 0.13/√0.117	
 
Standardised difference= 0.13/0.342	
 
Standardised difference= 0.380 
 
Using the above nomogram, a standardised difference of 0.380 with a pβ of 0.8 
and pα of 0.05, a sample size of 220 subjects is required to adequately power the 
study. There were 288 low and 124 high risk subjects (412 in total) in the study 
cohort. This means that the study is adequately powered to identify a clinical 
difference between low and high-risk subjects.  
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3.6.3 Sample size required to detect clinically significant difference between 
moderate and high-risk group 
 
Standardised difference= p1-p2/√(P (1- P) ) 
p1= minimum risk of CRC in high risk group = 0.2 or 20% 
p2 = minimum risk of CRC in moderate risk group = 0.17 or 17% 
 
P = (p1+p2)/2 
 
P = (0.2 + 0.17)/2		= 0.185 
 
Standardised difference= (0.2 − 0.17)/,0.185	(1 − 0.185)	
 
Standardised difference= 0.03/√0.151	
 
Standardised difference= 0.03/0.389	
	
Standardised difference= 0.077 
 
Using the above nomogram, a standardised difference of 0.077 with a pβ of 0.8 
and pα of 0.05, a sample size of 4000 subjects is required to adequately power 
the study. There were 124 high and 316 moderate risk subjects (440 in total) in 
the study cohort. This means that the study is substantially under-powered to 
identify a clinical difference between medium and high-risk subjects.  
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Chapter 4: Results 
 
4.1 Descriptive Statistics 
 
4.1.1 Cohort Characteristics 
 
For this study, 1120 patients in total presented in the clinical genetics department 
between 2000-2009 with a family history of colorectal cancer. From those, 183 
were excluded because of previous cancer or a previous colectomy and 3 more 
records were excluded as they did not have any FH of CRC. 22 records were 
excluded due to incomplete FH data.  A further 132 patients were excluded 
because they had a first degree relative (FDR) with a known mutation which 
predisposes to an increased risk of CRC, but they themselves tested negative of 
that mutation. In total, 780 patients met the criteria for inclusion. From those 
patients, 52 were referred for polyposis conditions; for the complete set of results 
for the polyposis patients, See Section 4.6.  
 
There was a total of 728 patients with a non-polyposis FH of CRC. The age of 
presentation in clinic ranged from 0 years 11 months to 84 years. The mean age 
of presentation was 44.948 (standard deviation (SD) ±12.2472) years and the 
median age was 44 years. All patients included had no personal history of CRC, 
however, there were 30 incidences of other cancers. The total patient years 
follow-up for cancer (excluding polyposis patients) was 5561. The mean number 
of years of follow up was 12.696 (SD ±2.8092) with a median of 13 years.  
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4.1.2 Family history structures and cancer history 
 
Table 12 summaries the incidence of each type of cancer in the patient cohort. It 
is worth mentioning that none of the patients that had a personal history of other 
cancer developed CRC later on.  
 
Table 12 Incidence of cancer in cohort. 
TYPE OF CANCER 
 
INCIDENCE 
Frequency % cohort 
BASAL CELL CARCINOMA 
MELANOMA 
CERVIX 
UTERUS 
BREAST 
BONE 
OVARY 
LUNG 
HAEMATOLOGICAL 
3 
3 
1 
5 
12 
1 
2 
1 
2 
0.41% 
0.41% 
0.14% 
0.69% 
1.65% 
0.14% 
0.27% 
0.14% 
0.27% 
TOTAL 30 4.12 % 
 
The FH structure from clinical notes is recorded in Table 13. 
 
Table 13 Family history structure of cohort. 
 Mean Range 
Minimum Maximum 
Sisters (Including 
half-sisters) 
1.22 0 10 
Brothers (Including 
Half-brothers) 
1.12 0 9 
Total number of 
siblings 
2.35 0 10 
Daughters 0.65 0 4 
Sons 0.64 0 4 
Total number of 
Children 
1.29 0 6 
Second Degree 
relatives 
10.82 4 39 
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Information regarding the incidence and percentage of the cohort who reported 
cancer in various family members is described in Table 14. The table is divided 
in incidence and percentage of family members presenting with CRC, other 
HNPCC associated cancer and other cancers. The most common relative 
reported with CRC was the mother (34.75%) and the most common affected 
relative with other HNPCC associated cancer  was the father (7.42%). From the 
patient cohort, there were 587 reports of CRC in a second degree relative. 
Table 14 Cancer incidence in relatives of the cohort. 
 Incidence in relative amongst cohort (N=728) 
N % of cohort 
Colorectal cancer incidence 
Mother 253 34.75% 
Father 240 32.97% 
Sibling(s) 192 26.37% 
Child(ren) 6 0.82% 
SDR 587 80.63% 
Other HNPCC associated cancer incidence* 
Mother 54 7.42% 
Father 58 7.97% 
Sibling(s) 59 8.10% 
Child(ren) 5 0.69% 
SDR 330 45.33% 
Other cancer incidence 
Mother 134 18.41% 
Father 62 8.52% 
Sibling(s) 86 11.81% 
Child(ren) 9 1.24% 
SDR 632 86.81 
*Other HNPCC cancer incidence included endometrial (females), gastric, ovarian 
(females), small bowel, bladder, brain, kidney, biliary tract, liver, gallbladder and 
pancreatic cancer. 
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Table 15 Shows family data regarding age of diagnosis of CRC and other 
HNPCC associated cancers in the whole cohort. 
Table 15 Mean age of relatives at cancer diagnosis.  
 Mean (±SD) Median 
Range 
Minimum Maximum 
Age of total FDRs and SDRs with 
CRC diagnosis 
59.635(±13.9764) 60 19 100 
Age of total FDRs and SDRs with 
HNPCC cancer diagnosis 
59.013(±14.8450) 60 11 95 
Age of FDRs with CRC diagnosis 57.110(±13.0720) 57 19 93 
Age of FDRs with HNPCC 
cancer diagnosis 
54.855(±15.0130) 54 11 87 
Age of Mother with CRC 
diagnosis 
59.780(±12.9384) 60 23 93 
Age of Mother with HNPCC 
cancer diagnosis 
58.137(±12.235) 55 27 87 
Age of Father with CRC 
diagnosis 
59.177(±12.1805) 59 20 87 
Age of Father with HNPCC 
cancer diagnosis 
61.782(±11.5706) 64 39 83 
Age of Sibling(s) with CRC 
diagnosis 
51.654(±12.1038) 50 28 78 
Age of Sibling(s) with HNPCC 
cancer diagnosis 
47.691(±13.9660) 50 11 76 
Age of Child(ren) with CRC 
diagnosis 
35.167(±9.4060) 36.5 19 46 
Age of Child(ren) with HNPCC 
cancer diagnosis 
24(±13.5499) 16 13 48 
Age of Total SDRs with CRC 
diagnosis 
62.801(±14.0262) 63 20 100 
Age of Total SDRs with HNPCC 
cancer diagnosis 
61.487(±14.1768) 62 20 95 
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4.1.3 BSG Risk Categories 
 
After assigning each patient to the corresponding BSG category according to FH 
and mutation status, there were 288 (39.56%) low-risk patients, 316 (43.41%) 
medium-risk and 124 (17.03%) high-risk patients. The mean age at presentation 
in these groups was 44.51 (SD±11.3022), 45.61 (SD±12.0352) and 44.26 
(SD±12.5681) respectively. One-way analysis of variance (ANOVA) 
demonstrated no significant difference when comparing the age of assessment 
amongst the three groups; F (2,725) = 0.836, p=0.434. Table 16 breaks down 
each FH subtypes that belong to each risk category. Of those in the moderate 
risk category, the majority (13.87%) had one FDR with CRC under the age of 50, 
which falls in the low-moderate sub-category. From those in the high-risk group, 
the majority (11.95%) were at risk of being an MMR gene carrier that fulfilled the 
Amsterdam Criteria. It is worth noting that 71 patients did not fully meet the BSG 
FH criteria and were assigned at appropriate risk by a panel of experts according 
to FH and clinical judgement.  
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Table 16 Percentage of cohort that fit into each family history category according to BSG guidelines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Frequency % of 
cohort 
Moderate risk  
 
Colorectal cancer in 1 FDR <50 years 
 
2 FDR ≥60 years in first degree kinship 
 
Colorectal cancer in 3 FDR in first degree kinship, none 
<50 years 
 
Colorectal cancer in 2 FDR in first degree kinship, mean 
age <60 years 
 
 
 
101 
 
82 
 
63 
 
 
70 
 
 
 
 
13.87% 
 
11.26% 
 
8.65% 
 
 
9.62% 
316 43.4% 
High risk 
 
Confirmed mutation carrier 
 
At risk HNPCC MMR carrier that Fulfils Amsterdam 
Criteria  
 
Untested FDR of proven mutation carrier 
 
1 FDR with MSI-H colorectal cancer AND IHC shows 
loss of MSH2, MSH6 or PMS2 expression. 
 
 
31 
 
87 
 
 
5 
 
1 
 
 
 
 
4.26% 
 
11.95% 
 
0.69% 
 
0.14% 
124 17.0% 
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4.1.4 Mutation testing 
 
From the cohort, 54 patients were tested and 31 of them were found to have a 
mutation that increased their risk of CRC and 2 had a variant of uncertain 
significance (VUS).  
 
There were 142 patients that had a relative tested without a mutation identified; 
however, 6 of them had a VUS. The complete set of results in terms of patients 
and their relatives that was tested is found in Table 17. Table 18 shows all the 
mutations identified in the cohort. 
 
Table 17 Percentage of cohort and their relatives that were tested for mutations in each risk category. 
 Patient Relative 
 N % Cohort N % Cohort 
Low risk 10 1.37% 30 4.12% 
Medium Risk 6 0.82% 80 10.99% 
High risk 38 5.22% 32 4.40% 
Total 54 7.4% 142 19.5% 
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Table 18 All Lynch syndrome mutations identified in the cohort and their frequency. 
Mutations Frequency 
MLH1 
MLH1 381-1 G>C  2 
MLH1 G67E mutation 1 
MLH1/A681T exon 18 1 
MLH1 c.1190delT 2 
MLH1 c.00G>A p.gly67Glu 1 
MLH1 pa681T exon 18  4 
MLH1/c.1017delC 2 
MLH1/R265C 1 
MLH1/E102D heterozygous   1 
MLH1 c.117-1G>C 1 
MLH1 c.473delA 1 
MSH2 
MSH2 c.628delAT  4 
MSH2 del exons 1-6  2 
MSH2c388_389delCA 1 
MSH6 
MSH6 c.3261dupC 1 
MSH6 c.3518_3519insA 1 
MSH6 del Exons 5-6  1 
Other 
PMS2 exon 7 deletion 1 
PMS2 c.137G>T  3 
Total 31 
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4.1.5 Number of years of follow-up 
 
The number of people years of follow up before CRC development for each 
BSG risk category is shown in Table 19. Patients were also divided according 
to age of presentation. 
 
Table 19 Follow-up years for each risk category according to age group for colorectal cancer development. 
 0-49 years  ≥ 50 years Total 
Low risk 943 433 1376 
Moderate risk 1825 1027 2852 
High risk Non-Mutation 
Carriers 
561 433 994 
Mutation 
Carriers 
248 91 339 
Total 3577 1984 5561 
 
 
Table 20 shows the number of people years of follow-up before polyp detection 
for each BSG risk category.  
 
Table 20 Follow-up years for each risk category according to age group for polyp detection. 
 0-49 years  ≥ 50 years Total 
Low risk 885 413 1298 
Moderate risk 1763 892 2655 
High risk Non-Mutation 
Carriers 
459 380 839 
Mutation 
Carriers 
228 91 319 
Total 3335 1776 5111 
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4.1.6 Cancer Development in cohort 
In total, 8 people developed colorectal adenocarcinoma from a cohort of 728. Of 
the eight cancers developed, two (25%) were in the low-risk category, three 
(37.5%) in the moderate-risk and three (37.5%) in the high-risk, including two 
mutation carriers. There was a significantly higher likelihood of cancer 
development in the mutation risk group compared to the low risk group (Fischer’s 
exact p=0.0485) but no other significant difference between categories (See 
Table 21 for complete set of results). The patients first presented to clinical 
genetics with a mean age of 54.710 (SD ± 17.2818), with median age of 62 and 
an age range of 28-79. The mean age of CRC diagnosis across all three 
categories was 63.460 years (SD ±14.0337) and the median age was 65 years, 
ranging from 38-79. The mean time from first presentation at clinical genetics to 
the development of CRC was 8.750 years (SD ± 5.8041), ranging from 0 to 16 
years.  
Table 21 Significance of colorectal cancer development between categories. 
Risk categories compared p-value (Fischer’s exact) 
Low & Moderate 
 
1.0000 
Low & High (including mutation carriers) 
 
0.1631 
Low & High (excluding mutation carriers) 
 
0.5692 
Low & Mutation carriers 
 
0.0485 
Low & Moderate plus High (Including mutation carriers) 
 0.4892 
Moderate & High (including mutation carriers) 
 0.3570 
Moderate & High (excluding mutation carriers) 
 1.0000 
Moderate & Mutation carriers 
 
0.0652 
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4.1.7 Polyp Detection in cohort 
 
In total, there were 65 patients with adenomatous polyps detected.  Of those 
people who had adenomatous polyps, 11 (16.9%) were in the low-risk group, 31 
(47.7%) in the moderate-risk group and 23 (35.4%) in the high-risk group, 
including five in the mutation carrier group. Fischer’s exact tests comparing the 
likelihood of polyp detection between categories is presented in Table 22. The 
low-risk group has a significantly lower chance of having a polyp detected 
compared to the moderate and high-risk groups, both including and excluding the 
mutation carriers. Furthermore, there was a significantly higher chance of polyp 
detection in the high-risk groups, including and excluding mutation carriers 
compared to the moderate risk group (p=0.0153 and p=0.0177 respectively). 
However, there was no significant difference in the likelihood of polyp detection 
between the moderate and mutation carrier groups (p=0.3475). Those patients 
first presented in the genetics clinic with a mean age of 47.785 years (SD 
±10.3688), median age 47 and age range 28-68. The age of first adenoma 
detection ranged from 31-74. The mean age of first adenomatous polyp detection 
was 53.416 (SD ± 11.2193), median age was 54. The mean time from first 
appointment in clinical genetics to adenoma development was 5.631 (SD ± 
4.8216) years and it ranged from 0-15 years. 
 
Table 22 Significance of polyp detection between categories. 
Risk categories compared p-value (Fischer’s exact) 
Low & Moderate 
 
0.0038 
Low & High (including mutation carriers) 
 
0.00001 
Low & High (excluding mutation carriers) 
 
0.00001 
Low & Mutation carriers 
 0.0126 
Low & Moderate plus High (Including mutation carriers) 
 0.0001 
Moderate & High (including mutation carriers) 
 0.0153 
Moderate & High (excluding mutation carriers) 
 0.0177 
Moderate & Mutation carriers 
 
0.3475 
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4.1.8 Cohort Summary 
 
Figure 8 summarises the data collection process and basic descriptive 
characteristics of the cohort.  
Figure 8 Summary of data collection process and cohort characteristics.  
 
 
 
 
 
 
 
 
Eligible Cohort (n=1120) 
Inclusion Criteria 
• Patient with Family History of CRC 
and HNPCC associated cancers 
• Unaffected by CRC 
• Referred to Tayside Genetics for risk 
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Patient tested negative of known familial 
mutation (n=132) 
 No FH of CRC (n=3) 
 
 
 Polyposis (n=52) 
 
 
 
Complete Cohort (n=782) 
 
 
 
 
Cohort (n=730) risk categorisation 
according to BSG criteria 
 
 
High Risk 
n=93 
 
 
 
Moderate risk 
n=316 
Low Moderate (n=183) 
High Moderate (n=133) 
 
 
 
Low risk 
n=288 
 
 
Colorectal Adenocarcinoma 
(n=8) 
 
 
Low  
n=11 
 
 
Moderate 
n=31 
 
 
Invasive Cancer or Adenomatous polyp developed in the cohort identified 
through Tayside pathology and endoscopy databases 
 
 
Adenomatous Polyp 
(n=65) 
 
 
Mutation 
Carriers 
n=31 
 
 
 
Mutation 
Carriers 
n=5 
 
 
High 
n=18 
 
 
Low  
n=2 
 
 
Moderate 
n=3 
 
 
High 
n=1 
 
 
Mutation 
Carriers 
n=2 
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4.2 Risk analysis 
 
4.2.1 CRC development by BSG category 
 
Mean age of cancer diagnosis for each group is shown in Table 23 and plotted 
in Figure 9. One-way ANOVA demonstrated no significant difference between 
age of presentation of CRC across the three risk categories, including and 
excluding mutation carriers (F(2,5)=0.0247, p=0.9757 and F(2,3)=0.5673, 
p=0.6180); however the number of cancers developed and thus analysed was 
small in each category, therefore the analysis is substantially underpowered. 
 
Table 23 Mean age of CRC development in each category.  
 Mean (±SD) Median Range 
Low risk 61.161(±15.1407) 61 46-76 
Moderate Risk 63.753(±2.7387) 64 61-67 
High Risk (including mutation carriers) 64.720(±18.9088) 77 38-79 
High Risk (excluding mutation carriers) 77(±0) 77 77 
Mutation carriers only 58.500(±20.500) 59 38-79 
Figure 9 Box plot for age of colorectal cancer development in each risk category. 
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4.2.2 Mean age of adenoma detection t by BSG category 
 
Mean age of polyp diagnosis for each group is described in Table 24 and plotted 
in Figure 10. One-way ANOVA demonstrated a significant difference between 
the age of first polyp development in the three risk groups when mutation carriers 
were included, (F(2,62)=5.2262, p=0.0080) and when excluded (F(2,57)=3.3300, 
p=0.0429). Three post-hoc Bonferroni-corrected independent-samples t-tests 
were conducted to examine the relationship between age and polyp 
development. These showed that the age of adenomatous polyp detection is 
significantly lower in the high-risk group relative to the moderate-risk group, 
including and excluding mutation carriers (p=0.0017 and p=0.0103 respectively). 
However, there was not a significant difference in the age of polyp detection 
between low and moderate-risk groups (p=0.2613) and low and high-risk groups 
(p=0.2723 including mutation carriers and p=0.4696 excluding mutation carriers). 
 
Table 24 Mean age of polyp detection in each category. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mean (±SD) Median Range 
Low risk 52.831(±11.3362) 50 34-74 
Moderate Risk 57.554(±10.3938) 58 33-74 
High Risk (including mutation carriers) 48.118(±9.8660) 51 31-65 
High Risk (excluding mutation carriers) 49.719(±9.0740) 52 31-65 
Mutation carriers only 42.351(±10.4331) 37 32-59 
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4.2.3 Independent T-test analysis 
 
In order to compare continuous variables with CRC development, independent 
T-test analysis was performed. The full results of the analysis can be found in 
Table 25. It should be noted that the significance values presented are not 
corrected for multiple comparisons.  
 
4.2.4. Pearson Chi-square/Fischer’s exact tests  
The full results of Pearson Chi-Square to compare the collected categorical 
variables with CRC can be found in Table 26. It should be noted that the 
significance values presented are not corrected for multiple comparisons.  
 
 
 
Figure 10 Box plot for age of adenomatous polyp detection in each risk category. 
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Table 25 Independent t-test analysis of continuous family history variables in relation to cancer development, including and excluding mutation carriers.  
 Including Mutation Carriers Excluding Mutation Carriers 
 Cancer Group 
(N=8) 
Non-Cancer Group 
(N=720) 
Independent t-
test 
Cancer Group 
(N=6) 
Non-Cancer 
Group(N=691) 
Independent t-test 
Variables M (±SD) M (±SD) F p M (±SD) M(±SD) F p 
Proportion of FDRs and SDRs affected with CRC 
 
Average age of all relatives at CRC diagnosis 
 
Proportion of FDRs affected with CRC 
 
Average age of FDRs at CRC diagnosis 
 
Proportion of SDRs affected with CRC 
 
Average age of SDRs at CRC diagnosis 
 
.129(±.0887) 
 
60.217(±13.5795) 
 
.292(±.3611) 
 
67.4000(±13.6675) 
 
.088(±.0819) 
 
54.133(±14.4714) 
.126(±.0884) 
 
58.628(±11.7103) 
 
.240(±.2054) 
 
56.285(±12.3884) 
 
.084(±.1024) 
 
63.337(±12.2442) 
.004 
 
.228 
 
5.739 
 
.000 
 
.493 
 
.003 
.918 
 
.741 
 
.696 
 
.047 
 
.913 
 
.097 
.120(±.1032) 
 
67.875(±8.5281) 
 
.353(±.4001) 
 
72.500(±8.6989) 
 
.063(±.0758) 
 
60.667(±16.0728) 
.127(±.0888) 
 
59.086(±11.5334) 
 
.242(±.2055) 
 
56.711(±12.2087) 
 
.085(±.1049) 
 
63.850(±12.0872) 
.275 
 
.788 
 
8.773 
 
.473 
 
.667 
 
.382 
.857 
 
.129 
 
.529 
 
.010 
 
.603 
 
.651 
Proportion of FDRs and SDRs affected with HNPCC cancer 
 
Average age of all relatives at HNPCC diagnosis 
 
Proportion of FDRs affected with HNPCC cancer 
 
Average age of FDRs at HNPCC diagnosis 
 
Proportion of SDRs affected with HNPCC cancer 
 
Average age of SDRs at HNPCC diagnosis 
 
.054(±.0563) 
 
68.250(±10.8819) 
 
.014(±.0393) 
 
67.000(±0) 
 
.066(±.0751) 
 
65.125(±16.4943) 
.045(±.0613) 
 
59.076(±14.4995) 
 
.055(±.1380) 
 
55.6509(±15.6100) 
 
.043(±.0720) 
 
60.805(±13.5949) 
.608 
 
.812 
 
3.127 
 
- 
 
.019 
 
.038 
.689 
 
.209 
 
.402 
 
.470 
 
.371 
 
.541 
.062(±.0615) 
 
72.833(±7.1822) 
 
.00(±.00) 
 
- 
 
.081(±.0816) 
 
72.833(±7.1822) 
.044(±.0605) 
 
59.739(±14.1624) 
 
.053(±.1369) 
 
- 
 
.043(±.0719) 
 
61.406(±13.5485) 
.275 
 
1.174 
 
4.140 
 
- 
 
.028 
 
1.093 
.490 
 
.111 
 
.000 
 
- 
 
.197 
 
.147 
Proportion of FDRs and SDRs affected with CRC and 
HNPCC 
 
Average age of all relatives at CRC and HNPCC diagnosis 
 
Proportion of FDRs affected with CRC and HNPCC 
 
Average age of FDRs at CRC and HNPCC diagnosis 
 
Proportion of SDRs affected with CRC and HNPCC 
 
Average age of SDRs at CRC and HNPCC diagnosis 
.183(±.1379) 
 
 
62.245(±13.5664) 
 
.306(±.3601) 
 
68.667(±11.4115) 
 
.155(±.1197) 
 
61.913(±16.0685) 
.171(±.1015) 
 
 
58.327(±11.0925) 
 
.295(±2237) 
 
56.205(±12.3959) 
 
.128(±.1234) 
 
62.597(±11.6592) 
.873 
 
 
.527 
 
3.784 
 
.044 
 
.017 
 
.928 
.741 
 
 
.390 
 
.890 
 
.025 
 
.539 
 
.890 
.182(±.1618) 
 
 
70.225(±7.1369) 
 
.353(±.4000) 
 
72.500(±8.6987) 
 
.144(±.1394) 
 
70.833(±10.6197) 
.171(±.1031) 
 
 
58.919(±10.7251) 
 
.295(±.2249) 
 
56.716(±12.0969) 
 
.128(±.1247) 
 
63.218(±11.4375) 
2.560 
 
 
.875 
 
6.153 
 
.314 
 
.248 
 
.002 
.804 
 
 
.036 
 
.739 
 
.009 
 
.758 
 
.185 
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 Including Mutation Carriers  Excluding Mutation Carriers  
Cancer Group Non-Cancer Group  Cancer Group Non-Cancer   
Variables Count (expected) Count (expected) df Chi2 p Count (Expected) Count (Expected) df Chi2 p 
1 affected FDR or SDR with CRC  
 
≥ 2 affected FDR or SDR with CRC  
 
≥ 3 affected FDR or SDR with CRC  
 
Parent affected with CRC 
 
Sibling affected with CRC 
 
Average age of relatives at CRC diagnosis <50 
 
Average age of relatives at CRC diagnosis <60 
 
0(3) 
 
6(4.3) 
 
3(1.7) 
 
5(5) 
 
2(1.9) 
 
2(1.2) 
 
3(3) 
271(286) 
 
381(382.7) 
 
152(153.3) 
 
448(448) 
 
168(168.1) 
 
131(131.8) 
 
313(313) 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
4.797 
 
1.550 
 
1.268 
 
.000 
 
.012 
 
.576 
 
.001 
.029 
 
.213 
 
.260 
 
.987 
 
.912 
 
.448 
 
.978 
0(2.2) 
 
4(3.2) 
 
2(1.3) 
 
4(3.8) 
 
2(1.4) 
 
0(.8) 
 
1(1.9) 
261(258.8) 
 
368(368.8) 
 
147(147.7) 
 
434(434.2) 
 
160(160.6) 
 
117(116.2) 
 
293(292.1) 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
3.623 
 
.430 
 
.515 
 
.038 
 
.345 
 
.944 
 
.834 
.057 
 
.512 
 
.473 
 
.846 
 
.557 
 
.311 
 
.361 
1 affected FDR or SDR with HNPCC associated cancer 
 
≥ 2 affected FDR or SDR with HNPCC associated cancer  
 
≥ 3 affected FDR or SDR with HNPCC associated cancer  
 
Parent affected with HNPCC associated cancer 
 
Sibling affected with HNPCC associated cancer 
 
Average age of relative at HNPCC cancer diagnosis <50 
 
Average age of relatives at HNPCC cancer diagnosis <60 
200(200.8) 
 
2(1.4) 
 
0(.3) 
 
0(1.1) 
 
1(.4) 
 
0(.9) 
 
1(1.8) 
3(2.2) 
 
122(122.6) 
 
24(23.7) 
 
104(102.9) 
 
32(32.6) 
 
69(68.1) 
 
137(1362.) 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
.372 
 
.363 
 
.276 
 
1.348 
 
1.186 
 
1.195 
 
.690 
.542 
 
.547 
 
.599 
 
.246 
 
.276 
 
.274 
 
.406 
3(1.7) 
 
1(1) 
 
0(.2) 
 
0(.8) 
 
0(.2) 
 
0(.7) 
 
0(1.3) 
 
197(198.3) 
 
111(111) 
 
21(20.8) 
 
97(96.2) 
 
29(28.8) 
 
63(62.3) 
 
125(123.7) 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
1.343 
 
.002 
 
.188 
 
.978 
 
.263 
 
.845 
 
2.311 
.247 
 
.968 
 
.665 
 
.323 
 
.608 
 
.358 
 
.128 
1 affected FDR or SDR with CRC or HNPCC cancer 
 
≥ 2 affected FDR or SDR with CRC or HNPCC cancer  
 
≥ 3 affected FDR or SDR with CRC or HNPCC cancer 
 
Parent affected with CRC or HNPCC cancer 
 
Sibling affected with CRC or HNPCC cancer 
  
Average age of relatives at CRC or HNPCC diagnosis <50 
 
Average age of relatives at CRC or HNPCC diagnosis <60 
0(1.8) 
 
6(5.9) 
 
5(3.5) 
 
5(5.8) 
 
3(2.1) 
 
2(1.1) 
 
2(3) 
161(159.2) 
 
530(530.1) 
 
310(311.5) 
 
526(525.2) 
 
189(189.9) 
 
124(124.9) 
 
344(343) 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
2.297 
 
.008 
 
1.219 
 
.447 
 
.516 
 
.904 
 
.708 
.130 
 
.529 
 
.270 
 
.504 
 
.473 
 
.342 
 
.400 
 
0(1.4) 
 
4(4.4) 
 
4(2.6) 
 
4(4.4) 
 
2(1.6) 
 
0(.6) 
 
0(1.9) 
158(156.6) 
 
504(503.6) 
 
300(301.4) 
 
506(505.6) 
 
179(179.4) 
 
106(105.4) 
 
318(316.1) 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
1.774 
 
.118 
 
1.308 
 
.130 
 
.171 
 
.776 
 
3.786 
.183 
 
.731 
 
.253 
 
.718 
 
.679 
 
.378 
 
.052 
Table 26 Chi2/Fischer’s exact tests  for categorical family history variables in relation to colorectal cancer development, including and excluding mutation carriers.   
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4.2.5 Frequency and percentage 10-year absolute risk of CRC 
 
The frequency of CRC diagnosis in the cohort by BSG risk category and age 
range is seen in Table 27, with mutation carriers shown both separately and 
included in the high-risk group. The % 10-year absolute risk (AR), based on 
people years of follow up in the cohort is shown for ages 0-49 and ≥50. The % 
10-year AR was calculated as below: 
!"#$%&	()	*+!*%&,	-!	+.%	*+/%.(&0
!"#$%&	()	0%+&,	()	)(11(2 − "4	-!	/ℎ+/	+.%	*+/%.(&0 	6	10	6	100 
 
e.g.  % 10-year AR for the low risk group, between ages 0-49: 
1
943 	6	10	6	100 = 1.06% 
Across all age ranges, the fewest cancer diagnoses occurred in the low-risk 
group. The lowest % 10-year AR was in the 0-49 age-group, in the low-risk 
category (1.06%). The highest absolute risk for CRC development for the ages 
0-49 was in the mutation carrier group (4.03%). The highest %10-year AR in ages 
≥50 was again in the mutation carrier group (10.99%) and in the high-risk group 
(3.82%) when combined with the mutation carriers.   
 
Table 27 Percentage 10-year absolute risk of colorectal cancer development for each risk category and age group, 
including and excluding mutation carriers.  
 Mutation carriers separate Mutation carriers included 
N 
Number of CRC (% 10-year absolute 
risk (95% CI)) 
N 
Number of CRC (% 10-year absolute 
risk (95% CI))  
Age range (Years) Age range (Years) 
Overall 0-49 ≥50 Overall 0-49 ≥50 
Low Risk 
288 2 
1 
1.06%  
(0.468-1.652) 
1 
2.31% 
(1.593-3.026) 
288 2 
1 
1.06%  
(0.468-1.652) 
1 
2.31% 
(1.593-3.026) 
Moderate 
Risk 
316 3 0 
3 
2.92% 
(2.201-3.640) 
316 3 0 
3 
2.92% 
(2.201-3.640) 
High Risk 
93 1 0 
1 
2.31% 
(1.372-3.292) 
124 3 
 
1 
1.24% 
(0.625-1.847) 
 
2 
3.82% 
(2.808-4.829) 
Mutation 
Carriers 31 2 
1 
4.03% 
(2.714-5.346) 
1 
10.99% 
(6.728-10.250) 
Total 728 8 2 6 728 8 2 6 
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4.2.6 Frequency and percentage 10-year absolute risk of adenomatous polyp 
detection 
 
Table 28 Shows the % 10-year risk of polyp detection in the cohort by BSG risk 
category and age range. Across all age ranges, the highest polyp detection was 
in the high-risk group. The % 10-year AR of polyp detection in the 0-49 age group 
was the highest in the high-risk group (28.32% and 26.20%, excluding and 
including mutation carriers respectively), and the lowest in the moderate-risk 
group (7.37%). For ages ≥50, the % 10-year AR was the highest in the moderate-
risk group (20.18%).  
 
Table 28 Percentage 10-year absolute risk of adenomatous polyp detection for each risk category and age group, 
including and excluding mutation carriers. 
 Mutation carriers separate Mutation carriers included 
N 
Number of adenomatous polyps (% 10-year 
absolute risk (95% CI)) 
N 
Number of adenomatous polyps (% 10-year 
absolute risk (95% CI))  
Age range (Years) Age range (Years) 
Overall 0-49 ≥50 Overall 0-49 ≥50 
Low Risk 
288 11 
8 
9.04% 
(8.177-9.904) 
3 
7.26% 
(6.110-8.418) 
288 11 
8 
9.04% 
(8.177-9.904) 
3 
7.26% 
(6.110-8.418) 
Moderate 
Risk 
316 31 
13 
7.37% 
(6.804-7.944) 
18 
20.18% 
(19.166-21.193) 
316 31 
13 
7.37% 
(6.804-7.944) 
18 
20.18% 
(19.166-21.193) 
High Risk 
93 18 
13 
28.32% 
(26.979-29.661) 
5 
13.16% 
(11.500-14.620) 
124 23 
18 
26.20% 
(25.143-27.257) 
5 
10.62% 
(6.605-14.635) Mutation 
Carriers 
31 5 
5 
21.93% 
(20.096-23.764) 
0 
Total 728 65 39 26 728 65 39 26 
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4.2.7 Relative risks and odds ratios for BSG risk categories 
 
Table 29 shows the RR and OR for the moderate and high-risk groups in 
comparison to the low risk group for the development of CRC. The mutation 
carriers are shown both as separate and included in the high-risk group. The RR 
and OR associated with both moderate and high-risk groups is also shown.  The 
only significant finding is the higher RR and OR of CRC in mutation carriers 
compared to the low-risk group.  
 
Table 29 Relative risks and Odds rations for colorectal cancer development in each category compared to the low-
risk group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Relative risk (95% CI) Odds ratio (95% CI) 
Moderate risk 1.367 (0.2301-8.1236) 1.371(0.2274-8.2619) 
High risk (including mutation 
carriers) 
3.484 (0.5894- 20.5928) 3.546(0.5850-21.4876) 
High risk (excluding mutation 
carriers) 
1.548 (0.1420-16.8830) 1.554 (0.1393-17.3401) 
Mutation carriers 9.290 (1.3557-63.6653) 9.862(1.3389-72.6439) 
Moderate or high 1.964 (0.3991-9.6622) 1.977 (0.3962-9.8635) 
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The RR and OR for the moderate or high-risk groups for the detection of 
adenomatous polyps is shown in Table 30. The highest RR and OR for polyp 
detection is in the high-risk group excluding the mutation carriers, followed by the 
high-risk group including the mutation carriers. The lowest RR and OR of polyp 
detection is in the moderate risk group. These values are significant, confirming 
that there is a higher RR and OR of detecting adenomatous polyps in the high-
risk groups compared to the low-risk group.  
 
 
Table 30 Relative risks and Odds rations for adenomatous polyp detection in each category compared to the low-risk 
group. 
 Relative risk (95% CI) Odds ratio (95% CI) 
Moderate risk 2.569 (1.3155-5.0148) 2.739 (1.3501-5.5571) 
High risk (including mutation 
carriers) 4.856 (2.4432-9.6529) 5.735 (2.6986-12.1857) 
High risk (excluding mutation 
carriers) 5.067 (2.4845-10.3355) 6.044 (2.7366-13.3473) 
Mutation carriers 4.223 (1.5690-11.3659) 4.8423 (1.5628-15.0063) 
Moderate or high 3.213 (1.7094-6.0399) 3.5223 (1.8090-6.8603) 
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4.2.8 Sensitivity, specificity, positive and negative predictive values of BSG risk 
categories 
 
The sensitivity, specificity, positive and negative predictive values (PPV, NPV) of 
the risk categories are shown in Table 31 for CRC development. These were 
calculated for the high-risk group, as well as the moderate and high-risk groups 
combined, compared with the low and moderate-risk groups and the low risk-
group respectively. The sensitivity and specificity for the high-risk group was 
2.42% and 99.17% respectively. Sensitivity was lower for the moderate and high-
risk groups combined (1.36%) but the specificity was greater (99.31%).  
 
 
Table 31 Sensitivity, specificity, PPV and NPV for colorectal cancer development. 
 Sensitivity (%) 
(95% CI) 
Specificity 
(%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
High-risk 2.42% 
(0.50-6.91) 
99.17% 
(98.08-99.73) 
37.50 
(12.68-71.25) 
83.19 
(82.79-83.59) 
Moderate & 
High risk 
1.36% 
(0.50-2.94) 
99.31 
(97.51- 99.92) 
75.00 
(37.88-93.66) 
39.72 
(39.37-40.07) 
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Table 32 shows the sensitivity, specificity, PPV and NPV of the BSG risk 
categories for adenomatous polyp development. The combined moderate and 
high-risk groups have the greater sensitivity (96.18%) but the specificity however 
is much poorer (12.27%). The high-risk group has a greater sensitivity (18.55%) 
but lower specificity (93.05%) in comparison to the combined groups. 
 
Table 32 Sensitivity, specificity, PPV and NPV for adenomatous polyp detection. 
 Sensitivity (%) 
(95% CI) 
Specificity 
(%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
High-risk 18.55% 
(12.14-26.52) 
93.05% 
(90.72-94.94) 
35.38% 
(25.49-46.71) 
84.77% 
(83.61-85.85) 
Moderate & 
High risk 
12.27% 
(9.36-15.71) 
96.18% 
(93.27-98.08) 
83.08% 
(72.31-90.22) 
41.78% 
(40.77-42.80) 
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4.3 Kaplan-Meier Analysis 
 
For the KM analysis, the reported p-values are the Log-Rank p-value.  
 
4.3.1 Cancer 
 
4.3.1.1 Low and moderate-risk group: 
 
Across the entire follow-up time period, two colorectal cancers were developed 
in the low-risk group and three colorectal cancers in the moderate-risk group. KM 
survival analysis demonstrated that there is no significant difference in the rate of 
CRC development between these two groups, p=0.681. Figure 11 shows the KM 
survival curve. 
 
 
Figure 11 KM analysis of colorectal cancer in the low and moderate-risk categories across total patient follow-up 
time. Log rank p=0.681. 
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4.3.1.2 Low and high-risk groups: 
 
There were three CRC’s in the high-risk group, including two that occurred in the 
confirmed mutation group, and two CRC’s in the low-risk group. There was no 
significant difference in the KM analysis of cancer free survival when comparing 
low and high-risk groups, both including and excluding mutation carriers (p=0.540 
and p=0.854 respectively). KM survival curves are shown in Figures 12 and 13. 
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Figure 13 KM analysis of colorectal cancer in the low and high-risk (excluding mutation carriers) categories across 
total patient follow-up time. Log rank p=854. 
Figure 12 KM analysis of colorectal cancer in the low and high-risk (including mutation carriers) categories across 
total patient follow-up time. Log rank p=540. 
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4.3.1.3 Low and increased risk groups: 
 
Across the follow-up time, there were two cancers in the low-risk group, and six 
cancers in the increased risk groups (three in each moderate and high-risk 
groups). When comparing the low and increased risk groups, there was no 
significant difference in cancer free survival, when including mutation carriers 
(p=0.995) and when excluding mutation carriers (p=0.697), (See Figures 14 and 
15 respectively).  
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Figure 15 KM analysis of colorectal cancer in the low and combined moderate and high-risk (excluding mutation 
carriers) categories across total patient follow-up time. Log rank p=0.697. 
Figure 14 KM analysis of colorectal cancer in the low and combined moderate and high-risk (including 
mutation carriers) categories across total patient follow-up time. Log rank p=0.995. 
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4.3.1.4 Moderate and high-risk groups: 
 
Across all follow-up periods, there were three colorectal cancers events in the 
moderate-risk group and three colorectal cancer events in the high-risk group, 
two of which occurred in confirmed mutation carriers. There was no significant 
difference in CRC development rate between moderate and high-risk groups, 
including and excluding mutation carriers (p=0.298 and p=0.978 respectively), 
See Figures 16 and 17. 
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Figure 16 KM analysis of colorectal cancer in the moderate and high-risk (excluding mutation carriers) categories 
across total patient follow-up time. Log rank p=0.978. 
Figure 17 KM analysis of colorectal cancer in the moderate and high-risk (including mutation carriers) 
categories across total patient follow-up time. Log rank p=0.298. 
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4.3.2 Adenomatous Polyps 
 
4.3.2.1 Low and moderate-risk group: 
 
Across all follow-up period, there 11 polyps were detected in the low-risk group 
and 31 polyps were detected in the moderate risk group. There was no significant 
difference on KM analysis when comparing polyp detection between these two 
groups, p=0.352. (See Figure 18).  
 
For the follow-up period for the age-group 0-49 years, there were 8 polyps in the 
low-risk group and 13 in the moderate-risk group. There was no significant 
difference in polyp detection between groups, p=0.669.  
 
For the follow-up period of ages 50 and above, 13 and 18 polyps were detected 
in the low and moderate-risk groups respectively. KM analysis was not significant 
(p=0.087).  
 
 
 
Figure 18 KM analysis of polyp detection in the low and moderate-risk categories across total patient follow-up 
time. Log rank p=0.352. 
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4.3.2.2 Low and high-risk groups: 
 
There were 23 polyps detected during the follow-up period in the high-risk group, 
in which 5 occurred in confirmed mutation carriers. There were 11 polyps 
detected in the low risk group. The likelihood of polyp detection in the high-risk 
group is significantly higher compared to the low-risk group, both when including 
and excluding mutation carriers, p=0.017 and p=0.014 respectively, see Figures 
19 and 20. 
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Figure 20 KM analysis of polyp detection in the low and high-risk (including mutation carriers) categories across 
total patient follow-up time. Log rank p=0.017. 
 
Figure 19 KM analysis of polyp detection in the low and high-risk (excluding mutation carriers) categories across 
total patient follow-up time. Log rank p=0.014. 
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For ages 0-49, there were 8 polyps in the low-risk group and 18 in the high-risk 
group, including 5 that were detected in mutation carriers. Polyp detection is 
significantly higher in the high-risk group compared to the low-risk group for ages 
0-49, both when including and excluding mutation carriers (p=0.006 and p=0.008 
respectively); see Figures 21 and 22. 
 
For ages 50 and above, there were 3 polyps detected in the low-risk group and 5 
in the high-risk group, with no polyps detected in the mutation carrier group. Polyp 
detection was not significant between groups, both including and excluding 
mutation carriers (p=0.584 and p=0.402 respectively). 
 
 
 
 
 
 
 
 
 
 
Figure 21 KM analysis of polyp detection in the low and high-risk (including mutation carriers) categories in ages 0-
49. Log rank p=0.006. 
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4.3.2.3 Low and increased risk groups: 
 
In the moderate and high-risk groups combined, 54 polyps were detected, 
including 5 in the mutation carrier group. Comparison of polyp detection between 
the increased risk groups with the low-risk group was not significant, p=0.119 
(including mutation carriers) and p=0.131 (excluding mutation carriers), shown in 
Figures 23 and 24. 
 
Below the age of 50, there were 8 polyps detected in the low-risk group and 31 
polyps in the increased risk groups without any statistical significance, including 
and excluding mutation carriers (p=0.384 and p=0.523 respectively). 
 
From the age of 50 and above, the increased risk groups had 23 polyps detected, 
none in the mutation carrier group. Survival analysis of polyp development 
including and excluding mutation carriers was not statistically significant (p=0.155 
and p=0.123 respectively). 
Figure 22 KM analysis of polyp detection in the low and high-risk (excluding mutation carriers) categories in ages 0-
49. Log rank p=0.008. 
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Figure 23 KM analysis of polyp detection in the low and combined moderate and high-risk (including mutation 
carriers) categories across total patient follow-up time. Log rank p=0.119. 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 KM analysis of polyp detection in the low and combined moderate and high-risk (excluding 
mutation carriers) categories across total patient follow-up time. Log rank p=0.131. 
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4.3.2.4 Moderate and high-risk groups: 
 
Across the follow-up period, 31 adenomatous polyps were detected in the 
moderate-risk category and 23 polyps in the high-risk category, 5 of which 
occurred in the mutation carrier group. On KM analysis, the rate of polyp detection 
between moderate and high-risk group was borderline significantly increased in 
the high-risk group when mutation carriers were included (p=0.053). Rate of polyp 
detection in high-risk group excluding mutation carriers was significantly higher 
compared to the moderate-risk group (p=0.042). KM curves shown in Figures 25 
and 26.  
 
When considering polyp free survival in patients 0-49 years of age, there were 
13 polyps in the moderate-risk group and 18 polyps in the high-risk group, 
including 5 in the mutation carrier group. People in high-risk group have a 
significantly higher rate of adenomatous polyps compared to the moderate risk 
group (p<0.001 for both including and excluding mutation carriers); see Figures 
27 and 28.  
 
In patient 50 years of age and above, 18 polyps were detected in the moderate 
risk group and 5 in the high-risk group, with no polyps in the mutation carrier 
group. KM analysis showed no significant difference in polyp rate between 
moderate and high-risk groups for people 50 and above, p=0.208 and p=0.412 
for high-risk group including and excluding mutation carriers respectively.  
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Figure 25 KM analysis of polyp detection in the moderate and high-risk (including mutation carriers) categories 
across total patient follow-up time. Log rank p=0.053. 
 
Figure 26  KM analysis of polyp detection in the moderate and high-risk (excluding mutation carriers) categories across 
total patient follow-up time. Log rank p=0.042. 
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Figure 27 KM analysis of polyp detection in the moderate and high-risk (including mutation carriers) categories in ages 0-49. 
Log rank p= <0.001. 
Figure 28 KM analysis of polyp detection in the moderate and high-risk (excluding mutation carriers) categories in ages 
0-49. Log rank p= <0.001. 
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4.3.3 KM Summary for Colorectal Cancer: 
A summary of the results of KM analysis comparing rates of colorectal cancer 
diagnoses between different BSG risk categories across all age ranges is shown 
in Table 33. P-values shown are KM Log-Rank p-values.  
Table 33 Summary of survival analysis data  for colorectal cancer development. 
BSG Groups Being Compared KM Log-Rank (p-value)  
 
Low and Moderate 
 
 
0.681 
 
 
Low and High (Including mutation carriers) 
 
0.540 
 
Low and High (Excluding mutation carriers) 
 
 
0.854 
 
 
Low and Moderate/High (Including mutation 
carriers) 
 
0.995 
 
Low and Moderate/High (Excluding mutation 
carriers) 
 
0.697 
 
Moderate and High (Including mutation carriers) 
 
 
0.298 
 
 
Moderate and High (Excluding mutation carriers) 
 
 
0.978 
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4.3.4 KM Summary for Polyp detection: 
 
Table 34 summarises the results of KM analysis comparing rates of 
adenomatous polyp detection between different BSG risk categories across all 
age ranges, 0-49 age group and ≥50 age group. P-values shown are KM Log-
Rank p-values. Significant results are highlighted in bold. 
 
Table 34 Summary of survival analysis data  for adenomatous polyp detection. 
BSG Groups Being Compared KM Log-Rank (p-value) 
 Total Follow-up 
Time 0-49 ≥50 
 
Low and Moderate 
 
0.352 0.669 0.087 
 
Low and High (Including mutation 
carriers) 
 
0.017 0.006 0.584 
 
Low and High (Excluding mutation 
carriers) 
 
0.014 0.008 0.402 
 
Low and Moderate/High (Including 
mutation carriers) 
 
0.119 0.384 0.155 
 
Low and Moderate/High (Excluding 
mutation carriers) 
 
0.131 0.523 0.123 
 
Moderate and High (Including mutation 
carriers) 
0.053 <0.001 0.208 
 
Moderate and High (Excluding mutation 
carriers) 
 
0.042 <0.001 0.421 
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4.4 Summary  
Table 35 shows summary information of the frequency and % 10-year absolute risk of CRC, KM analysis and RR for each BSG risk group. 
Table 35 Summary table for colorectal cancer development. 
A) 
Number of 
people 
Number of Cancers (% 10-year absolute risk) 
KM log rank 
p-value 
Overall RR (95% CI) 
  Overall 0-49 >50 Overall  
Low 288 2 
1 
1.06% (0.468-1.652) 
1 
2.31% (1.593-3.026) 
- - 
Moderate 316 3 0 
3 
2.92% (2.201-3.640) 
0.681 1.367 (0.2301-8.1236) 
High (excluding mutation carriers) 93 1 0 
1 
2.31% (1.372-3.292) 
0.854 1.548 (0.1420-16.8830) 
Moderate/High (excluding mutation carriers) - - - - 0.697 - 
Mutation carriers only 31 2 
1 
4.03% (2.714-5.346) 
1 
10.99% (6.728-10.250) 
- 9.290 (1.3557-63.6653) 
Total 728 8 2 6   
 
B) 
Number of 
people 
 
Number of Cancers (% 10-year absolute risk) 
KM log rank 
p-value 
Overall RR (95% CI) 
  Overall 0-49 >50 Overall  
Low 288 2 
1 
1.06% (0.468-1.652) 
1 
2.31% (1.593-3.026) 
- - 
Moderate 316 3 0 
3 
2.92% (2.201-3.640) 
0.681 1.367 (0.2301-8.1236) 
High (Including Mutation carriers) 124 3 
1 
1.24%(0.625-1.847) 
2 
3.82% (2.808-4.829) 
0.540 3.484 (0.5894-20.5928) 
Moderate/High - - - - 0.995 1.964 (0.3991-9.6622) 
Total 728 8 2 6   
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Table 36 shows summary information of the frequency and % 10-year absolute risk of polyps, KM analysis and RR for each BSG risk group.  
Table 36 Summary table for polyp detection. 
A) 
Number 
of people 
Number of Polyps (% 10-year absolute risk) KM log rank p-value Overall RR (95% CI) 
  Overall 0-49 >50 Overall 0-49 ≥50  
Low 288 11 
8 
9.04% (8.177-9.904) 
3 
7.26% (6.110-8.418) - - - - 
Moderate 316 31 
13 
7.37% (6.804-7.944) 
18 
20.18% (19.166-21.193) 0.352 0.669 0.087 2.569(1.3155-5.0148) 
High (excluding mutation carriers) 93 18 
13 
28.32% (26.979-29.661) 
5 
13.16% (11.500-14.620) 0.014 0.008 0.402 
5.067(2.4845-
10.3355) 
Moderate/High (excluding mutation 
carriers) 
- - - - 0.131 0.523 0.123 - 
Mutation carriers only 31 5 
5 
21.93% (20.096-23.764) 0 - - - 
4.223(1.5690-
11.3659) 
Total 728 65 39 26     
 
B) 
Number 
of people 
 
Number of Polyps (% 10-year absolute risk) KM log rank p-value Overall RR (95% CI) 
  Overall 0-49 >50 Overall 0-49 ≥50  
Low 288 11 
8 
9.04% (8.177-9.904) 
3 
7.26% (6.110-8.418) - - - - 
Moderate 316 31 
13 
7.37% (6.804-7.944 
18 
20.18% (19.166-21.193) 0.352 0.669 0.087 2.569 (1.3155-5.0148) 
High (Including Mutation carriers) 124 23 
18 
26.20% (25.143-27.257) 
5 
10.62% (6.605-14.635) 0.017 0.006 0.584 4.856 (2.4432-9.6529) 
Moderate/High - - - - 0.119 0.384 0.155 3.213 (1.7094-6.0399) 
Total 728 65 39 26     
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4.5 Polyposis conditions 
 
4.5.1 Cohort Characteristics 
 
In total there were 52 patients that presented to Clinical Genetics with polyposis 
conditions. Overall, the age of presentation ranged from 0 years and two months 
to 69 years. The mean age of presentation was 32.716 (SD ± 18.0630) and the 
median age was 32 years. All the patients had no history of CRC, and they were 
excluded if they had undergone any type of colectomy. The total patient years 
follow-up for CRC was 337. The mean number of patient years of follow-up was 
9.629 (SD ± 4.9862), with a median of 11 years.  
 
4.5.2 Family history structures and cancer history 
 
Table 37 summarises the FH data extracted from clinical notes. 
 
Table 37 FH structure of polyposis cohort. 
 Mean Range Minimum Maximum 
Sisters (Including 
half-sisters) 
0.88 0 4 
Brothers (Including 
Half-brothers) 
1.15 0 6 
Total number of 
siblings 
2.03 0 8 
Daughters 0.37 0 2 
Sons 0.62 0 4 
Total number of 
Children 
0.98 0 4 
Second Degree 
relatives 
9.42 4 32 
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Incidence and percentage of cohort with CRC in various family members is 
described in Table 38. The table also reports incidence of gastric and other type 
of cancers. The most common FDR reported with CRC was the father (17.31%) 
followed by mother and siblings (11.53% each). Even though polyposis 
conditions are associated with increased risk of stomach cancer, the only FDR 
with an incidence of stomach cancer was the father (3.85%). 
Table 38 Cancer incidence in relatives of the polyposis cohort.  
 Incidence in relative amongst cohort (N=52) 
N % of cohort 
Colorectal cancer incidence 
Mother 6 11.53% 
Father 9 17.31% 
Sibling(s) 6 11.53% 
Child(ren) 1 1.92% 
SDR 31 59.62% 
Stomach cancer incidence 
Mother 0 - 
Father 2 3.85% 
Sibling(s) 0 - 
Child(ren) 0 - 
SDR 8 15.38% 
Other cancer incidence 
Mother 7 13.46% 
Father 2 3.85% 
Sibling(s) 6 11.53% 
Child(ren) 0 - 
SDR 32 61.54% 
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Family data regarding age of diagnosis of CRC in the cohort is shown in Table 
39. 
Table 39 Age of cancer development in relatives of polyposis cohort. 
 Mean (±SD) Median 
Range 
Minimum Maximum 
Age of total FDRs and SDRs with 
CRC diagnosis 
51.18 
(±14.539) 
54 26 81 
Age of FDRs with CRC diagnosis 44.28(±12.091) 40 26 77 
Age of Mother with CRC 
diagnosis 
53.67(±17.461) 49 35 77 
Age of Father with CRC diagnosis 38.88(± 9.636) 36 26 62 
Age of Sibling(s) with CRC 
diagnosis 
47.33 (±8.260) 50.5 34 55 
Age of Child(ren) with CRC 
diagnosis 
41 (±0) 41 41 41 
Age of Total SDRs with CRC 
diagnosis 
55.96 
(±14.165) 
59 26 81 
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4.5.3 BSG Risk Categories and Mutation Testing 
 
BSG Guidelines assign patients with polyposis conditions into high risk category, 
but have different screening recommendations according to Family History, 
Mutation testing and any type of colon surgery. Table 40 shows the percentage 
of the cohort that fits into each BSG category. What is not included in the table is 
FAP patients post colectomy or post procto-colectomy as they were excluded 
from the study.  
 
Table 40 Frequency of patients in each risk BSG risk category. 
 
 
 
From the 52 patients in the polyposis cohort, 1 tested positive for MAP mutations 
and 2 for PJS and another 37 were APC mutation carriers. From the 37 APC 
mutation carriers, 19 had mutations that predispose to FAP,14 had mutations that 
predispose to Attenuated FAP and 2 tested positive for a Variant of Uncertain 
Significance (VUS). From the cohort, there were 7 patients that had a family 
member with FAP with no mutation identified and another 3 that themselves 
fulfilled the clinical FAP criteria with no mutation identified. The complete set of 
identified mutations and their frequencies is found in Table 41. 
 
 
 
BSG category Frequency (N) % of Cohort  
 
At risk FAP (Member of FAP family with no 
mutation identified) 
 
Fulfils clinical FAP criteria  
 
Proven APC mutation carrier opting for deferred 
surgery 
 
MUTYH-associated polyposis (MAP) 
 
Peutz-Jeghers syndrome (PJS) 
 
FDR of proven mutation carrier 
 
 
7 
 
 
3 
 
37 
 
 
1 
 
2 
 
2 
 
13.5% 
 
 
5.8% 
 
71.2% 
 
 
1.9% 
 
3.8% 
 
3.8% 
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Table 41 Confirmed pathogenic mutations for polyposis conditions identified in the cohort. 
Mutations Frequency 
Familial Adenomatous Polyposis 
APC exon 13 1660c>t 2 
APC c.694C>T,p. (Arg 232*) 2 
APC 5757 5772 del 16bp 7 
APC c.5979delT 3 
APC 5760-5776 del 16bp 1 
APC 1753delC  1 
APC 288T>A exon 3 14 
APC 5461/2delA 1 
Apc15.4 exon 3374InsT 1 
APC 5461/2delA 1 
APC gene deletion 1 
APC c 222-2A>g 1 
MYH associated polyposis 
MUTYHpGly3965Asp]+[=] 1 
Peutz-Jeghers syndrome 
STK11 790delTTGA 1 
STK11 c.1529_1533delTCAAA 1 
Total 38 
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4.5.4 Number of years of follow-up 
 
From the whole cohort, 35 patients were followed-up for colonoscopic screening. 
Table 42 Shows the number of years of follow-up of the polyposis patients until 
cancer incidence or first adenomatous polyp development, according to age 
group. 
 
Table 42 Colorectal cancer and polyp follow-up of patients. 
 0-49 years  ≥ 50 years Total 
Cancer Follow-up 295 42 337 
Polyp Follow-up 211 29 240 
 
4.5.5 Cancer development and polyp detection in cohort 
 
Overall, no patient developed cancer in this cohort. However, 18 (34.6%) of the 
cohort had a colectomy either before or after the start of follow-up.  
 
From the 35 patients that were followed up, 18 (51.43 %) of them had 
adenomatous polyps detected. Those patients first attended clinical genetics with 
a mean age of 38.6937(SD ± 15.1021), median age 42 and age range of 7-64. 
The mean time from first appointment to adenoma detection was 3.833 years (SD 
±4.5922). The average age of polyp detection in the cohort was 41.325 years (SD 
±13.6902), with a median age of 43. 
 
Across the polyposis cohort, no patient developed gastric cancer during the 
follow-up period. Additionally, only 6 (11.54%) patients have had a gastric polyp 
identified, in which only two (33.33%) were sessile, the rest (66.67%) were 
hyperplastic.  
 
 
 
 
 
 
 116 
 
4.5.6 Cohort summary 
Figure 29 summarises the basic descriptive characteristics of the polyposis 
cohort.  
Figure 29 Summary of selection process and descriptive characteristics of the polyposis cohort. 
 
 
 
 
 
 
 
 
Eligible Cohort (n=1120) 
Inclusion Criteria 
• Patient with Family History of CRC 
and HNPCC associated cancers 
• Unaffected by CRC 
• Referred to Tayside Genetics for risk 
assessment from 2000-2009 
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Previous CRC or previous colectomy 
(n=183) 
Incomplete FH data (n=22) 
Patient tested negative of known familial 
mutation (n=132) 
 No FH of CRC (n=3) 
 
 
 
Polyposis (n=52) 
 
 
 
Complete Cohort (n=782) 
 
 
 
 
Cohort (n=730) risk 
categorisation according to 
BSG criteria 
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mutation 
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Fulfils 
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(n=0) 
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through Tayside pathology and endoscopy databases 
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Chapter 5: Discussion 
 
5.1 Cohort Characteristics 
 
From the data collection, 782 patients met the inclusion criteria. Of those patients, 
728 had a FH of colorectal cancer without an identifiable polyposis syndrome. In 
total, there were 5561 patient years of follow-up for risk of CRC, with mean 
number of years of follow-up per person being 12.696 (SD ±2.8092). The patient 
years of follow-up for polyp detection was 5111, with a mean of 11.669 years 
(SD±4.0581). Patient years follow-up were less for polyps than cancer, as more 
polyps were detected during follow-up, thus more patients became censored. The 
mean age of presentation to clinical genetics was 44.948 years old (SD± 
12.2472). When considering family structures and cancer history, a wide variation 
in presentation was found. Interestingly, the most common FDR presenting with 
CRC was the mother (34.75%) and with other HNPCC cancers was the father 
(7.97%). The average age of any FDR being diagnosed with CRC or HNPCC 
associated cancer is 57.110 (SD±13.0720) years and 54.855 (SD±15.0130) 
years respectively.  
 
5.2 BSG Risk category 
 
5.2.1 Assigning BSG risk 
 
In total, 288 (39.56%) patients were assigned to a low-risk, 316 (43.41%) patients 
were assigned to a moderate-risk and 124 (17.03%) patients were assigned to a 
high-risk category according to BSG criteria, suggesting a reasonable distribution 
of patients between each group. Since the mean age at presentation of each 
group was not significantly different, the likelihood of follow-up time at certain 
ages being significantly different is low. When considering risk categories, the 
majority (60.44%) of the patients that attended the genetics clinic had an 
increased risk of developing CRC. In the moderate-risk group, the most common 
FH presentation was CRC in 1 FDR <50 years of age (13.87%). In the high-risk 
group, the most common FH presentation was people at risk of HNPCC MMR 
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carriers that fulfil the Amsterdam Criteria, without an identifiable mutation 
(11.95%). The family histories used to assign patients their correct risk categories 
were retrieved from FH questionnaires sent to the patients, pedigrees and clinical 
letters; where possible, these were confirmed by the relevant cancer registry. 
Studies have demonstrated that patient-reported cancer family history is accurate 
when it comes to colorectal cancer risk assessment and that over-reporting is 
rare. Therefore, although it is important to consider over-reporting biases in 
different cancers, the risk of over-reporting in the current data and results for 
colorectal cancer is likely to be low and thus risk assignment is likely to closely 
reflect the actual risk in this case.(184,185) There may be small discrepancies 
when a relative had metastatic cancer without primary cancer identification, 
nevertheless, this did not occur often.  
 
5.2.2 Potential discrepancies in BSG risk criteria 
 
While assigning patients to the BSG risk categories, some potential pitfalls were 
identified.  Firstly, the guidelines were interpreted in the literal sense for the 
purposes of the study as the aim was to assess the utility of the current risk 
stratification guidelines. Therefore, for example, the criteria for moderate-low risk 
group include CRC in 1 FDR <50 years. Thus, a patient with a FDR with CRC 
diagnosed at 51 may be placed into the low-risk category even though their risk 
may be the same as the person diagnosed at 49. Furthermore, the criteria only 
included First- and Second-degree relatives in a first-degree kinship. It can be 
argued that a relative more distant than second-degree does not share enough 
genetic material with the patient to be relevant to a polygenic mode of inheritance. 
However, since the penetrance of CRC and other HNPCC associated cancers is 
not 100%, it may be that the patient’s aunt is yet to develop the condition, in which 
a higher risk may be re-assigned at a later stage.  
 
Furthermore, even though both age and number of relatives are included in the 
risk stratification, it can be argued that the BSG guidelines use age as the key 
determinant when assigning a patient to a risk group, as family structure is not 
considered. This is because the guidelines fail to address the potential impact of 
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the size of the family in risk stratification. For example, a person whose mother is 
affected with CRC and also has two siblings, both affected with CRC may be at 
a greater risk from a relative whose mother is affected with CRC and has six 
siblings, in which only two of them are affected with CRC. The model also fails to 
take into account the gender of relatives. BSG criteria state that the lifetime risk 
of CRC is higher in males (1 in 5) rather than in females (1 in 13), which may 
result in misplacing patients in a higher or lower risk category, depending on their 
relatives’ gender.(37)   
 
Similarly, there may be cases where there is one CRC and two other HNPCC 
associated cancers, none less than the age of 50, in which the patient does not 
meet Amsterdam and therefore high-risk criteria. The same patient will not even 
meet the moderate-high risk criteria, as there is no mention of other HNPCC 
cancers, except for CRC. In cases such as the above, the judgement of the 
clinician and genetic counsellor will determine the risk category in which the 
patient will be assigned to. These exceptions allow for subjective interpretation of 
the guidance amongst different centres, which may limit the reliability of risk 
categorization and have a downstream effect on the follow-up screening 
recommendations. A universal guidance that takes into account some of these 
discrepancies would have been desirable to avoid this element of uncertainty.  
 
5.3 Mean age of CRC development and polyp detection amongst 
different risk groups 
 
5.3.1 Mean age of cancer development is not significantly different between 
groups 
 
The mean age of the patients at CRC diagnosis for each risk group is shown in 
Table 23, Section 4.2.1. One-way ANOVA demonstrated no significant 
difference between age of presentation of CRC across the risk categories. Even 
though the high-risk group would have been expected to have a lower age of 
CRC diagnosis, increased screening in the high-risk group potentially results in 
successful prevention of cancers at a younger age.  
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5.3.2 Mean age of Polyp detection is significantly different between groups 
 
The age of adenomatous polyp detection is significantly lower in the high-risk 
group relative to the moderate-risk group. This is consistent with previous studies, 
which have found that people with familial CRC are at risk of adenoma formation 
at an earlier age.(172,186) This may also explain the above findings of no 
difference in age presentation of CRC’s between groups, as if polyps are detected 
early through colonoscopic screening in the high-risk patients, they can be 
adequately excised and followed up, reducing CRC development. Therefore, this 
result supports the recommendation of colonoscopy being performed from an 
earlier age in high-risk groups.  
 
5.4 There is greater risk of CRC development in the mutation group 
 
As shown in Table 27, Section 4.2.5, eight cancers developed overall, with two 
cancers in the low-risk group, three in the moderate-risk group and three in the 
high-risk group. Two of the cancers occurred in patients less than 50 years of age 
(one in the low-risk and one in the mutation group), whereas the rest occurred in 
patients ≥50 years old.  
In this cohort, the % 10-year absolute risk (AR) from age 0-49 for each category 
was 1.06% for the low-risk group and 1.236% for the high-risk group (including 
the mutation carriers). The mutation carrier group on its own had a 10-year % AR 
of 4.03%. In the age group ≥50, the % 10-year AR for development of CRC for 
the low, moderate and high-risk was 2.31%, 2.92% and 3.82% respectively. The 
mutation carrier group on its own had a % 10-year AR of 10.99%.  
Thus, the mutation group has a higher risk for CRC development compared to 
the rest of the groups. Furthermore, the RR and OR for CRC development was 
significantly higher in the mutation carrier group. This is consistent with other 
studies that showed that people with Lynch syndrome have a higher risk of CRC 
development.(108,109)  
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5.5 There is no difference in risk of CRC development between low 
and high-risk groups 
 
In ages 0-49, there was no CRC development in the high-risk group. For people 
aged ≥50, the % 10-year AR for development of CRC for the low-risk group and 
for the high-risk group (excluding mutation carriers), was 2.31% for both. 
Additionally, the RR and OR for CRC development was not significant in either of 
these categories.  
 
From available data, there is evidence that CRC risk is greater in the high-risk 
group compared to the general population. The fact that there is no difference in 
CRC risk between these groups across the two age categories suggests that the 
recommended screening surveillance is effective in reducing the risk of CRC in 
high-risk groups.   
 
5.6 There is a greater risk of polyp detection in high-risk groups 
compared to the low-risk group 
 
Overall there were 65 polyps detected across all age groups, 11 in the low, 31 in 
the moderate and 18 in the high-risk groups. In the 0-49 age category, 39 polyps 
were detected and in the ≥50 age category, 26 polyps were detected.  
 
In the present study, the % 10-year absolute risk of polyp detection for the low, 
moderate and high-risk groups were 9.04%, 7.37% and 26.20% respectively for 
the age group 0-49. The latter value included mutation carriers, whereas the risk 
rises to 28.32% when the mutation carriers are excluded. Overall, the greatest 
risk for polyp detection was in the high-risk group, which is consistent with other 
studies.(172,186) For ages ≥50, the risk was 7.26% for the low, 20.18% for the 
moderate and 10.62% for the high-risk group (and 13.62% when excluding 
mutation carriers). It is also worth noting that no mutation carriers developed 
polyps in this age group, which may be explained in a number of ways. Firstly, 
mutation carriers may be predisposed to develop polyps at an earlier age, as 5 
polyps were detected in the 0-49 age group. Secondly, the increased 
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colonoscopic surveillance before the age of 50 may account for the earlier polyp 
detection and excision. 
 
Moreover, there was an increasing trend for RR and OR of polyp detection across 
BSG categories. The risk for polyp detection was significantly higher for the high-
risk group excluding mutation carriers. The results demonstrate that there is an 
increased risk of polyps in the increased-risk groups compared to the low-risk 
group across all age categories, which is consistent with the findings of other 
studies.(186) The risk also seems to be greater in the 0-49 age category. 
 
5.7 There is no significant difference in the rate of CRC development 
between BSG risk groups 
 
To determine the difference in follow-up time for CRC diagnosis between groups, 
KM analysis was used. The number of CRC cases in the low and medium-risk 
groups were two and three respectively. In the high-risk group there were three 
CRC diagnoses, two of them which occurred in mutation carriers. There was no 
significant difference in CRC development rates when comparing low and 
medium, low and high as well as moderate and high-risk groups. Furthermore, 
no significant difference was detected when comparing low and increased risk 
groups (i.e. moderate and high-risk groups combined). Separate analysis 
including and excluding mutation carriers from the high-risk group yielded no 
significant differences in the rate of CRC development when compared to the 
moderate-risk group. 
 
From the above findings, it can be argued that the rate of CRC development in 
the high-risk group is no different compared to the low-risk group, thus, two-yearly 
colonoscopic screening is not required. On the other hand, it can be argued that 
the fact that there is no difference in the rate of CRC is due to the increased 
colonoscopic screening. In order for these hypotheses to be tested, a randomised 
controlled trial (RCT) should be conducted where half of the high-risk group is 
exposed to regular colonoscopic screening, in comparison to the other half which 
does not. However, this would not be realistic due to the ethical implications of 
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not screening the high-risk group which are known to have a higher risk of cancer 
development.  
 
5.8 Polyp detection rate is significantly higher in the high-risk group 
compared to the low and moderate-risk groups, especially in the 0-
49 age category 
 
When comparing low and high-risk groups, the rate of polyp detection was 
significantly greater in the high-risk group across all follow-up time. This was true 
both when including and excluding mutation carriers from the high-risk category. 
When age-dependent analysis was performed, it showed that there was a 
significantly higher risk of polyp detection in the high-risk group, only in the 0-49 
age group. The rate of polyp development was significantly higher in the high-risk 
group compared to the moderate-risk group, both when including and excluding 
mutation carriers across all follow-up period. When age-group specific analysis 
was performed, there was a significantly higher rate in polyp detection in the high-
risk groups in the 0-49 age group, when excluding mutation carriers.  
 
Even though the above findings showed that there is no difference in CRC risk 
and rate between low and high-risk groups, polyp risk and rate are greater in the 
high-risk group. Thus, it can be argued that colonoscopic surveillance is 
necessary to identify adenomatous polyps at an early stage and prevent 
adenoma-carcinoma development.  
 
5.9 Medium-risk patients do not require increased surveillance 
before the age of 50 
 
Moderate-risk group had no CRC development and the lowest 10-year % AR of 
polyp development compared to the rest of the groups. RR and OR showed that 
CRC development in the moderate risk group is not significantly higher compared 
to the low-risk group and that risk of polyp detection is less than the high-risk 
group. KM analysis showed that there is no significant difference in CRC 
development or polyp detection rate between the low and the moderate-risk 
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groups. Additionally, there was a significantly greater likelihood of polyp 
development in the higher-risk group compared to the moderate-risk group in 0-
49 age category. 
 
The above findings indicate that colonoscopic screening in the moderate-risk 
group before the age of 50 might not be required. This is consistent with the BSG 
guidelines which do not recommend any screening prior to this age for the 
moderate-risk group. In order to be able to draw further conclusions regarding 
the recommended screening frequency, analysis of the moderate-risk group 
should be separated into moderate-low and moderate-high risks, due to the fact 
that these two sub-categories have different screening recommendations.  
 
5.10 Further work is required to demonstrate the benefit of 
screening in high-risk patients aged 50 years or more 
 
From the present cohort, no difference was found in CRC rates between 
moderate and high-risk groups, both including and excluding the mutation 
carriers. This is conflicting with the results on polyp rates, which demonstrates 
that the high-risk group has a significantly higher rate of polyp detection 
compared to the low and moderate-risk groups, especially in the 0-49 age group. 
However, these data may not indicate a true connection between high-risk 
patients and polyp development, but rather a finding caused by the frequent 
screening of the high-risk group compared to the other two groups.  
 
After the age of 50, survival analysis showed no difference in the rate of polyp 
detection in the high-risk group when compared to the low and moderate-risk 
groups. Furthermore, the RR and OR for CRC development in the high-risk group 
excluding the mutation carriers were non-significant when compared to the low-
risk groups and the % 10-year risk of CRC was exactly the same as the low-risk 
group.  
 
From the above findings, it may be reasonable to decrease the frequency of 
screening in patients at high-risk (excluding mutation carriers) after the age of 50.   
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Nevertheless, this should be firstly confirmed by having a larger patient cohort, to 
allow for smaller age-group analysis and thus give more information regarding 
CRC risk of high-risk patients above the age of 50.  
 
5.11 Current family history guidelines are not good predictors of 
cancer risk 
 
No conclusive predictors could be identified from the data that would increase 
cancer risk. This was true when including and excluding mutation carriers. 
Moreover, analysis of the high-risk and moderate and high-risk groups combined 
showed that the categories have very poor sensitivity, even though specificity is 
good. This means that theoretically, people might have been placed in the low-
risk category due to FH, even though they belonged in a higher risk group.  
 
As seen from the results, higher risk groups have an increased risk and rate of 
adenomatous polyp detection. Adenomas may be detected and excised, 
preventing cancer development. Thus, FH of adenomas could be potentially 
incorporated into the guidelines. For a more accurate risk stratification, FH as 
well as environmental factors that are known to increase CRC risk should be used 
in a polygenic risk assessment model.  
 
5.12 Screening recommendations for polyposis patients is effective 
 
In this study, only 52 patients were identified with polyposis conditions. 18 of 
those patients had a colectomy either before or after the start of follow-up. From 
the patients that were followed-up, nobody developed colorectal cancer, despite 
the increased risk in polyposis mutation carriers. Even though no risk or survival 
tests were carried out, the BSG guidelines seem to be give effective 
recommendations in regard to this risk group and achieving the reduction in 
cancer. 
 
A prospective study with similar methodology should be conducted for polyposis 
patients including those with partial colectomies to identify risk of polyps and 
colorectal cancer and further evaluate screening recommendations. 
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5.13 Strengths and limitations of the study 
 
5.13.1 Strengths 
To the authors’ knowledge, this is the first study to attempt to assess the 
recommendations of the BSG guidelines. The methodology presented in the 
study allows to assess the effectiveness of the guidelines considering a 
comprehensive list of variables such as CRC and polyps, and FH taking into 
account CRC and other HNPCC cancers. Unfortunately, it was not feasible to 
have a larger cohort due to time constraints, but the design of the study is 
relatively simple and adaptable, so this can be replicated in other centres with 
larger cohorts. The method can also be replicated to expand the analysis on 
polyposis, assessing the effectiveness of the guidelines if there is a larger cohort.  
Another strength of the study is the FH information gathered for each individual. 
The database used provides a detailed structure of FH for a very large cohort of 
patients, which can be used in the future for continuation of this work or other 
types of research. The fact that the age of presentation to the clinic was not 
significantly different across the groups means that the results were not biased 
in terms of age. The medium-risk group had the most patients, followed closely 
by the low-risk group. The high-risk group had around half the patients compared 
to the other two groups and the mutation carriers consisted only a small 
proportion of that group (25%) which would be the trend expected in a population. 
Furthermore, the study is adequately powered to detect differences of colorectal 
cancer risk between low and moderate and between low and high-risk groups, as 
indicated by the power analyses. There were also 5561 years of follow-up which 
are considered a sizable amount for this patient cohort.  
5.13.2 Limitations 
 
Firstly, this cohort study was performed retrospectively. People eligible for this 
study had no personal history of CRC themselves and the FH information used 
was collected from pedigrees and clinic communications. The fact that the 
patients were sent out family history questionnaires minimises the risk of recall 
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bias during the appointment, as they had time to investigate and ask relatives. 
However, HNPCC is associated with a number of different types of cancer and 
sometimes it can be difficult to identify all of them during family history. 
Nevertheless, when permission was granted, cancer registries were used to 
identify the exact type of cancer and age of relatives, adding an extra layer of 
accuracy in the reported histories. Despite these limitations, family-history 
questionnaires are thought to be accurate in collecting information for 
CRC.(184,185) 
 
Due to the fact that the FH were taken at initial assessment, changes in FH after 
further mutation testing or further cancer development were not taken into 
account. Thus, the risk assignment of some people might have changed over the 
years. This limitation could have been avoided in a prospective study, recruiting 
patients and following them up over many years. Nonetheless, the aim of the 
study was to assess the effectiveness of the guidelines at assigning risk of the 
patients, and thus initial risk assessment is important.  
 
Another limitation of the study was the fact that some information that would have 
been useful for the study was not present in the clinical notes. Patients with more 
than 50% of data missing were excluded from the study, decreasing the sample 
size. In a prospective study design, this could have been avoided by ensuring 
specific FH protocols and improved history taking. Due to time limitations, 
prospective data collection to address the study aims was not feasible. As the 
BSG guidelines recommend excision of all adenomatous polyps, regardless of 
size, it was not possible to assess the adenoma-carcinoma progression. 
However, this link is well established and just separate analysis of adenoma 
detection in the cohort might be deemed sufficient.(172) 
 
Due to the low number of cancers in each group, it was not feasible to divide the 
population into smaller age groups for risk analysis. Colorectal cancer rates were 
analysed using the categories of 0-49 and ≥50 years of age, which are relatively 
broad. These categories seemed appropriate as early colorectal cancer is 
generally defined as being developed in ages <50. Dividing the ≥50 category into 
50-59 and ≥60 would have been more desirable to identify whether there is a 
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difference in smaller age groups, had there been more cancer incidences in the 
cohort. If the sample size and follow-up years were larger along with the cancer 
and polyp incidence, it would have been viable to also calculate the % 5-year 
absolute risk.  
 
Another important limitation of the study was the fact that it was underpowered 
when comparing moderate and high-risk groups, thus the results must be 
interpreted with caution. Nevertheless, the study was still adequately powered to 
identify risks between low and moderate and between low and high-risk groups.  
As a pilot study, it still demonstrates the methodology that can be applied to a 
population with an adequate power to produce more confident results. 
 
5.14 Conclusions 
 
The results suggest that the mutation carrier group have a higher risk of CRC 
development, thus should be screened regularly, as per the current BSG 
guidelines. The risk and rate of CRC development does not differ between low 
and high-risk groups, indicating that the increased screening in the high-risk 
patients is effective. However, it may be reasonable to reduce screening in the 
high-risk group (excluding mutation carriers) above the age of 50.  
 
Furthermore, the results re-affirm that screening for the moderate risk group 
below the age of 50 may be unnecessary, and there is some evidence to suggest 
that the high-risk group may be eligible for less frequent screening. There is no 
evidence to suggest less frequent screening in the mutation carrier group.  
This study demonstrates a feasible methodology that could be expanded to other 
genetic centres in Scotland in order to generate a large sample size for 
addressing the research questions. If replicated, the results presented could have 
implications for screening recommendations in terms of how at-risk people are 
identified, and therefore early detection and prevention strategies. 
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5.15 Future work 
 
5.15.1 Increased sample size  
 
In order to be able to answer questions regarding the effectiveness of risk 
assignment and screening recommendations with certainty, this study needs to 
be adequately powered and performed in a prospective fashion. Retrospective 
power calculation showed that a sample size of 4000 people would be adequate, 
ideally spread evenly between groups.  Since there is a difference in lifetime risk 
of CRC amongst genders, it would be preferable for the power calculations to be 
tailored to males and females. In Tayside, only 1120 patients presented to clinical 
genetics enquiring about their risk of colorectal cancer in a ten-year period. Thus, 
it is likely that collection of these data from larger centres across the whole of 
Scotland would achieve a substantial cohort size. A multi-centre approach would 
require communications with specialists to interpret the guidance in a 
standardised way, however, developing these guidelines is beyond the scope of 
this study. The information gathering stage of this study took approximately 8 
months part-time, including having to extract data from different databases. 
Depending on accessibility of local databases, it would be possible to collect data 
from a larger cohort in a reasonable timeframe. Ideally, a cohort study such as 
this should be conducted prospectively, however this would require several years 
of follow-up. Furthermore, recording of FH should be complete and double-
checked from available registries if possible, to create a reliable database 
identifying families at an increased risk. 
 
5.15.2 Survival and cost-benefit analysis 
 
The main outcome of the screening recommendations is to reduce mortality of 
people with increased risk of colorectal cancer, rather than just identify them. This 
cohort only identified eight patients with CRC, which are not enough to analyse 
survival.  
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The study should also be extended to include a cost-benefit analysis of the 
screening programme, to identify the cost to run the colonoscopies so frequently 
and the overall benefit to the patients. This can also be compared with cost-
benefit analysis from the Scottish Bowel screening programme. If the cancer free 
survival of the increased risk patients is significant, this would outweigh the cost.  
 
5.15.3 Improving sensitivity of the guidance 
 
The sensitivity of the guidance in this cohort was poor, thus improving this would 
also be beneficial. In order to avoid false negatives and improve the sensitivity of 
the study, it may be worthwhile looking at other family members and exploring 
history in more detail. Sensitivity can also be improved by including data on 
adenomatous polyps of relatives.  
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